Polymer factor ix moiety conjugates

ABSTRACT

Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.12/499,770, filed Jul. 8, 2009, which is a continuation of U.S. patentapplication Ser. No. 11/172,459, now U.S. Pat. No. 7,579,444, filed Jun.30, 2005, which claims the benefit of priority to U.S. ProvisionalPatent Application Ser. No. 60/584,505, filed Jun. 30, 2004, all ofwhich are incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates generally to conjugates comprising aFactor IX moiety (i.e., a moiety having Factor IX activity) and apolymer. In addition, the invention relates to compositions comprisingthe conjugates, methods for synthesizing the conjugates, methods fordelivering the conjugates, and methods for treating patients.

REFERENCE TO SEQUENCE LISTING, TABLE OR COMPUTER PROGRAM

A Sequence Listing is being submitted electronically via EFS in the formof a text file, created Dec. 14, 2009 and named“417148302US05seqlist.txt” (4348 bytes), the contents of which areincorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

Hemostasis is the process of arresting the outflow of blood from aninjured blood vessel. For mammals, as well as many other organisms, thehemostatic process is critically important for continued survival.Defects in the hemostatic process can result in, for example, theinability to effectively form blood clots that serve to stop the loss ofblood following vascular injury. In humans, individuals who suffer froman inability to form blood clots are called hemophiliacs. Of particularconcern for hemophiliacs is the life-threatening risk that once started,bleeding will never cease.

Generally, hemophiliacs lack the ability to produce effective amounts ofone or more substances ultimately required for the transformation ofsoluble fibrinogen into insoluble fibrin. For example, hemophiliacs whosuffer from hemophilia B (also called “congenital factor IX deficiency”and “Christmas disease”) have an inability to produce effective levelsof Factor IX. Factor IX is a key component of one of several “cascades”of reactions that result in the formation of blood clots. Critical forthe cascade of reactions referred to as the “intrinsic pathway,” FactorIX ultimately influences the conversion of fibrinogen into the majorcomponent of blood clots, fibrin.

Although the process by which blood clots are formed is relativelycomplex, the role of Factor IX in the intrinsic pathway can be describedbriefly. When blood comes into contact with negatively charged surfacesand/or subendothelial connective tissues (as a result of, for example,tissue damage associated with a laceration), Factor XII (or Hagemanfactor) in the presence of other substances is transformed into FactorXIIa. Factor XIIa (along with other substances) transforms Factor XIinto Factor XIa. In turn, Factor XIa (along with other substances)transforms Factor IX into Factor IXa. Factor VIII, Factor IXa, calciumions and phospholipid micelles form a lipoprotein complex with Factor Xand activate it to form Factor Xa. Thereafter, Factor Xa (along withother substances) converts prothrombin into thrombin, with the resultthat a relatively large amount of thrombin is produced over time.Relatively large amounts of thrombin convert fibrinogen into fibrin.Fibrin, in turn, forms the matrix or lattice responsible for theformation of blood clots. Factor IX's role in the intrinsic pathway ofblood clotting is shown schematically below.

Affecting one out of 34,500 males, hemophilia B can result from any oneof a variety of mutations of the Factor IX gene, which is located on theX-chromosome. Depending on the particular mutation, hemophilia B canmanifest itself as severe, moderate or mild. Individuals suffering fromthe severest forms of hemophilia B entirely lack the ability to expressactive forms of Factor IX. Clinically, individuals affected withhemophilia B suffer from nose bleeds, easy bruising, joint hemorrhage,and prolonged bleeding from wounds. Current treatment of hemophilia Binvolves the infusion of exogenous Factor IX concentrate collected fromhuman plasma or prepared via recombinant DNA techniques. Because thesetreatments serve only to supplement the lack of effective levels ofFactor IX, individuals suffering from severe forms of hemophilia Brequire regular injections (as often as three times a week) of Factor IXconcentrate throughout their lives. Patients suffering from even moremoderate forms of hemophilia B often require injection of Factor IXconcentrate before and/or following surgery and dental work.

Several commercial forms of Factor IX concentrates are available toprovide replacement therapy for patients suffering from hemophilia B.For example, blood-derived Factor IX complex products (containing otherfactors) are sold under the BEBULIN VH® (Baxter Healthcare, Vienna,Austria), KONYNE 80® (Bayer Corporation, Eikhart Ind.), PROFILNINE SD™(Alpha Therapeutic Corporation, Los Angeles Calif.), and PROPLEXT®(Baxter Healthcare, Glendale Calif.) brands. Somewhat more purifiedforms of Factor IX products are sold under the ALPHANINE SD® (AlphaTherapeutic Corporation, Los Angeles Calif.) and MONONINE® (AventisBehring, Kankakee Ill.) brands. With respect to recombinantly preparedFactor IX concentrates, one product is currently available under theBENEFIX® (Wyeth/Genetics Institute, Cambridge Mass.) brand.

Generally, the recombinant source of Factor IX concentrate is favoredover blood-derived sources since the latter involves the risk oftransmitting viruses and/or other diseases. In addition, purity is oftenhigher with the recombinant source, thereby avoiding potential problemsarising from administering unwanted blood factors and other proteinsgenerally present in blood-derived sources.

Notwithstanding the benefits of administering a recombinant-basedformulation, the processing of recombinant-based products often requiresthe presence of certain proteins such as albumin, which can be presentin the final formulation administered to the patient. As a result,patients who receive such formulations develop allergic reactions tothese foreign proteins. In any event, both blood-derived andrecombinant-based products suffer from the disadvantage of repeatedadministration.

PEGylation, or the attachment of a poly(ethylene glycol) derivative to aprotein, has been described as a means to reduce immunogenicity as wellas a means to prolong a protein's in vivo half-life. With respect toFactor IX, however, previous approaches for forming protein-polymerconjugates suffered from several deficiencies.

For example, U.S. Pat. No. 5,969,040 describes a process comprising thestep of oxidizing vicinal diols of carbohydrate moieties in theactivation region of Factor IX to form aldehydes. Following theoxidizing step, the described process includes the step of covalentlyattaching one or more non-antigenic polymers [such as ahydrazine-bearing poly(ethylene glycol) derivative] to the oxidizedcarbohydrate moieties. A problem with this approach, however, is theincreased complexity attributed to the additional steps required toobtain an oxidized form of Factor IX. In addition, any oxidizers thatmay remain following the oxidation step may degrade the polymerassociated with the conjugate. Finally, this approach is limited toconjugation using specific polymers (i.e., hydrazide-containingpolymers) and specific regions on Factor IX (i.e., vicinal diols ofcarbohydrate moieties in the activation region of Factor IX).

The presence of oxidizers (present either as a result of the processdescribed in U.S. Pat. No. 5,969,040, or from other causes) introducesadditional challenges with respect to providing an acceptablepharmaceutical product of a polymer conjugated to Factor IX.Specifically, methionine and other hydroxyl-containing amino acids maybe subject to unwanted oxidation in the presence of oxidizers, therebyintroducing aldehyde groups. Any residual aldehydes not reacted with thepolymeric reagent will be reactive and can potentially damage theprotein. In order to address this problem, unreacted aldehydes need tobe capped with glycine or other small molecule to stabilize the protein.In doing so, however, an analytical problem arises in that forregulatory purposes, a product should be readily defined; theintroduction of additional components can frustrate otherwisestraightforward product definition. In particular, the use of cappingagents would present a particularly difficult challenge.

U.S. Pat. No. 6,037,452 describes attachment of a poly(alkylene oxide)to Factor IX, wherein attachment to Factor IX is effected through apoly(alkylene oxide) bearing one of the following reactive groups:triazine, acetyl, hydrazine, diazonium, amino, and succinimidyl ester.Again, however, the reference lacks disclosure of effecting attachmentthrough polymers bearing reactive groups other than triazine, acetyl,hydrazine, diazonium, amino, or succinimidyl ester.

Thus, there remains a need in the art to provide additional conjugatesbetween water-soluble polymers and moieties having Factor IX activity.In particular, there is a need to provide more simple processes forconjugating a polymer to a moiety having Factor IX activity. The presentinvention is therefore directed to such conjugates as well ascompositions comprising the conjugates and related methods as describedherein, which are believed to be new and completely unsuggested by theart.

SUMMARY OF THE INVENTION

Accordingly, in one or more embodiments of the invention, a conjugate isprovided, the conjugate comprising a Factor IX moiety covalentlyattached, either directly or through a spacer moiety comprised of one ormore atoms, to a water-soluble polymer, wherein the molecular weight ofthe water-soluble polymer is greater than 5,000 Daltons and less thanabout 150,000 Daltons.

In one or more embodiments of the invention, a conjugate is provided,the conjugate comprising a Factor IX moiety covalently attached at anamino acid residue, either directly or through a spacer moiety comprisedof one or more atoms, to a water-soluble polymer, wherein the amino acidresidue is not attached, either directly or though the spacer moiety,via a —CH₂—C(O)—O—, —N(H)—C(O)CH₂—O—, —C(O)—N(H)—, —N(H)—C(O)—CH₂—O—,—C(O)—CH₂—O—, —C(O)—CH₂—CH₂—C(O)—O—, diazo, or triazine linkage.

In one or more embodiments of the invention, a conjugate is provided,the conjugate comprising a Factor IX moiety covalently attached, eitherdirectly or through a spacer moiety comprising of one or more atoms to anon-linear water-soluble polymer.

In one or more embodiments of the invention, a composition is provided,the composition comprising a plurality of conjugates, wherein at leastabout 80% of all conjugates in the composition are each comprised of aFactor IX moiety covalently attached to one, two, three or fourwater-soluble polymers, and further wherein for each water-solublepolymer in the conjugate, the Factor IX moiety is attached eitherdirectly or through a spacer moiety comprised of one or more atoms. Thecompositions encompass all types of formulations and in particular thosethat are suited for injection such as powders that can be reconstituted,as well as liquids (e.g., suspensions and solutions).

In one or more embodiments of the invention, a method for preparing aconjugate is provided, the method comprising adding a polymeric reagentcomposition to a Factor IX composition under conditions sufficient toresult in a conjugate comprising a Factor IX moiety covalently attached,either directly or through a spacer moiety comprised of one or moreatoms, to a water-soluble polymer.

In one or more embodiments of the invention, a method for delivering aconjugate is provided, the method comprising administering to thepatient a composition comprising a conjugate as described herein. Thestep of administering the conjugate can be effected by injection (e.g.,intramuscular injection, intravenous injection, subcutaneous injection,and so forth) or other approach.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 and FIG. 2 are copies of gels resulting from sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis ofsamples described in Examples 1 through 4.

FIG. 3 is a copy of a gel resulting from SDS-PAGE analysis of samplesdescribed in Examples 5, 6, 10 and 11.

FIG. 4 is a copy of a gel resulting from SDS-PAGE analysis of samplesdescribed in Examples 2, 9 and 12 through 16.

FIG. 5 is a plot corresponding to the resulting conjugation solution ofExample 1.

FIG. 6 is a plot corresponding to the resulting conjugation solution ofExample 2.

FIG. 7 is a plot corresponding to the resulting conjugation solution ofExample 3.

FIG. 8 is a plot corresponding to the resulting conjugation solution ofExample 4

FIG. 9 is a plot corresponding to the resulting conjugation solution ofExample 12.

FIG. 10 is a plot corresponding to the resulting conjugation solution ofExample 13.

FIG. 11 is a plot corresponding to the resulting conjugation solution ofExample 14.

FIG. 12 is a plot corresponding to the resulting conjugation solution ofExample 15.

DETAILED DESCRIPTION OF THE INVENTION

Before describing one or more embodiments of the present invention indetail, it is to be understood that this invention is not limited to theparticular polymers, synthetic techniques, Factor IX moieties, and thelike, as such may vary.

It must be noted that, as used in this specification and the claims, thesingular forms “a,” “an,” and “the” include plural referents unless thecontext clearly dictates otherwise. Thus, for example, reference to “apolymer” includes a single polymer as well as two or more of the same ordifferent polymers, reference to “an optional excipient” refers to asingle optional excipient as well as two or more of the same ordifferent optional excipients, and the like.

In describing and claiming the present invention, the followingterminology will be used in accordance with the definitions describedbelow.

“PEG,” “polyethylene glycol” and “poly(ethylene glycol)” as used herein,are interchangeable. Typically, PEGs for use in accordance with theinvention comprise the following structure “—(OCH₂CH₂)_(n)—” where (n)is 2 to 4000. As used herein, PEG also includes“—CH₂CH₂—O(CH₂CH₂O)_(n)—CH₂CH₂—” and “—(OCH₂CH₂)_(n)O—,” depending uponwhether or not the terminal oxygens have been displaced. Throughout thespecification and claims, it should be remembered that the term “PEG”includes structures having various terminal or “end capping” groups andso forth. The term “PEG” also means a polymer that contains a majority,that is to say, greater than 50%, of —OCH₂CH₂— repeating subunits. Withrespect to specific forms, the PEG can take any number of a variety ofmolecular weights, as well as structures or geometries such as“branched,” “linear,” “forked,” “multifunctional,” and the like, to bedescribed in greater detail below.

The terms “end-capped” and “terminally capped” are interchangeably usedherein to refer to a terminal or endpoint of a polymer having anend-capping moiety. Typically, although not necessarily, the end-cappingmoiety comprises a hydroxy or C₁₋₂₀ alkoxy group, more preferably aC₁₋₁₀ alkoxy group, and still more preferably a C₁₋₅ alkoxy group. Thus,examples of end-capping moieties include alkoxy (e.g., methoxy, ethoxyand benzyloxy), as well as aryl, heteroaryl, cyclo, heterocyclo, and thelike. It must be remembered that the end-capping moiety may include oneor more atoms of the terminal monomer in the polymer [e.g., theend-capping moiety “methoxy” in CH₃O(CH₂CH₂O)_(n)—] or not [e.g., “CH₃”in CH₃(OCH₂CH₂)_(n)—] In addition, saturated, unsaturated, substitutedand unsubstituted forms of each of the foregoing are envisioned.Moreover, the end-capping group can also be a silane. The end-cappinggroup can also advantageously comprise a detectable label. When thepolymer has an end-capping group comprising a detectable label, theamount or location of the polymer and/or the moiety (e.g., active agent)to which the polymer is coupled can be determined by using a suitabledetector. Such labels include, without limitation, fluorescers,chemiluminescers, moieties used in enzyme labeling, colorimetricmoieties (e.g., dyes), metal ions, radioactive moieties, and the like.Suitable detectors include photometers, films, spectrometers, and thelike. The end-capping group can also advantageously comprise aphospholipid. When the polymer has an end-capping group comprising aphospholipid, unique properties are imparted to the polymer and anyresulting conjugate. Exemplary phospholipids include, withoutlimitation, those selected from the class of phospholipids calledphosphatidylcholines. Specific phospholipids include, withoutlimitation, those selected from the group consisting ofdilauroylphosphatidylcholine, dioleylphosphatidylcholine,dipalmitoylphosphatidylcholine, disteroylphosphatidylcholine,behenoylphosphatidylcholine, arachidoylphosphatidylcholine, andlecithin.

“Non-naturally occurring” with respect to a polymer as described herein,means a polymer that in its entirety is not found in nature. Anon-naturally occurring polymer may, however, contain one or moremonomers or segments of monomers that are naturally occurring, so longas the overall polymer structure is not found in nature.

The term “water soluble” as in a “water-soluble polymer” is any polymerthat is soluble in water at room temperature. Typically, a water-solublepolymer will transmit at least about 75%, more preferably at least about95%, of light transmitted by the same solution after filtering. On aweight basis, a water-soluble polymer will preferably be at least about35% (by weight) soluble in water, more preferably at least about 50% (byweight) soluble in water, still more preferably about 70% (by weight)soluble in water, and still more preferably about 85% (by weight)soluble in water. It is most preferred, however, that the water-solublepolymer is about 95% (by weight) soluble in water or completely solublein water.

Molecular weight in the context of a water-soluble polymer, such as PEG,can be expressed as either a number-average molecular weight or aweight-average molecular weight. Unless otherwise indicated, allreferences to molecular weight herein refer to the weight-averagemolecular weight. Both molecular weight determinations, number-averageand weight-average, can be measured using gel permeation chromatographyor other liquid chromatography techniques. Other methods for measuringmolecular weight values can also be used, such as the use of end-groupanalysis or the measurement of colligative properties (e.g.,freezing-point depression, boiling-point elevation, or osmotic pressure)to determine number-average molecular weight or the use of lightscattering techniques, ultracentrifugation or viscometry to determineweight-average molecular weight. The polymers of the invention aretypically polydisperse (i.e., number-average molecular weight andweight-average molecular weight of the polymers are not equal),possessing low polydispersity values of preferably less than about 1.2,more preferably less than about 1.15, still more preferably less thanabout 1.10, yet still more preferably less than about 1.05, and mostpreferably less than about 1.03. As used herein, references will attimes be made to a single water-soluble polymer having either aweight-average molecular weight or number-average molecular weight; suchreferences will be understood to mean that the single-water solublepolymer was obtained from a composition of water-soluble polymers havingthe stated molecular weight.

The terms “active” or “activated” when used in conjunction with aparticular functional group, refer to a reactive functional group thatreacts readily with an electrophile or a nucleophile on anothermolecule. This is in contrast to those groups that require strongcatalysts or highly impractical reaction conditions in order to react(i.e., a “non-reactive” or “inert” group).

As used herein, the term “functional group” or any synonym thereof ismeant to encompass protected forms thereof as well as unprotected forms.

The terms “spacer moiety,” “linkage” and “linker” are used herein torefer to an atom or a collection of atoms optionally used to linkinterconnecting moieties such as a terminus of a water-soluble polymerand a Factor IX moiety or an electrophile or nucleophile of a Factor IXmoiety. The spacer moiety may be hydrolytically stable or may include aphysiologically hydrolyzable or enzymatically degradable linkage.

“Alkyl” refers to a hydrocarbon chain, typically ranging from about 1 to15 atoms in length. Such hydrocarbon chains are preferably but notnecessarily saturated and may be branched or straight chain, althoughtypically straight chain is preferred. Exemplary alkyl groups includemethyl, ethyl, propyl, butyl, pentyl, 1-methylbutyl, 1-ethylpropyl,3-methylpentyl, and the like. As used herein, “alkyl” includescycloalkyl as well as cycloalkylene-containing alkyl.

“Lower alkyl” refers to an alkyl group containing from 1 to 6 carbonatoms, and may be straight chain or branched, as exemplified by methyl,ethyl, n-butyl, i-butyl, and t-butyl.

“Cycloalkyl” refers to a saturated or unsaturated cyclic hydrocarbonchain, including bridged, fused, or Spiro cyclic compounds, preferablymade up of 3 to about 12 carbon atoms, more preferably 3 to about 8carbon atoms. “Cycloalkylene” refers to a cycloalkyl group that isinserted into an alkyl chain by bonding of the chain at any two carbonsin the cyclic ring system.

“Alkoxy” refers to an —O—R group, wherein R is alkyl or substitutedalkyl, preferably C₁₋₆ alkyl (e.g., methoxy, ethoxy, propyloxy, and soforth).

The term “substituted” as in, for example, “substituted alkyl,” refersto a moiety (e.g., an alkyl group) substituted with one or morenoninterfering substituents, such as, but not limited to: alkyl, C₃₋₈cycloalkyl, e.g., cyclopropyl, cyclobutyl, and the like; halo, e.g.,fluoro, chloro, bromo, and iodo; cyano; alkoxy, lower phenyl;substituted phenyl; and the like. “Substituted aryl” is aryl having oneor more noninterfering groups as a substituent. For substitutions on aphenyl ring, the substituents may be in any orientation (i.e., ortho,meta, or para).

“Noninterfering substituents” are those groups that, when present in amolecule, are typically non-reactive with other functional groupscontained within the molecule.

“Aryl” means one or more aromatic rings, each of 5 or 6 core carbonatoms. Aryl includes multiple aryl rings that may be fused, as innaphthyl or unfused, as in biphenyl. Aryl rings may also be fused orunfused with one or more cyclic hydrocarbon, heteroaryl, or heterocyclicrings. As used herein, “aryl” includes heteroaryl.

“Heteroaryl” is an aryl group containing from one to four heteroatoms,preferably sulfur, oxygen, or nitrogen, or a combination thereof.Heteroaryl rings may also be fused with one or more cyclic hydrocarbon,heterocyclic, aryl, or heteroaryl rings.

“Heterocycle” or “heterocyclic” means one or more rings of 5-12 atoms,preferably 5-7 atoms, with or without unsaturation or aromatic characterand having at least one ring atom that is not a carbon. Preferredheteroatoms include sulfur, oxygen, and nitrogen.

“Substituted heteroaryl” is heteroaryl having one or more noninterferinggroups as substituents.

“Substituted heterocycle” is a heterocycle having one or more sidechains formed from noninterfering substituents.

An “organic radical” as used herein shall include alkyl, substitutedalkyl, aryl and substituted aryl.

“Electrophile” and “electrophilic group” refer to an ion or atom orcollection of atoms, that may be ionic, having an electrophilic center,i.e., a center that is electron seeking, capable of reacting with anucleophile.

“Nucleophile” and “nucelophilic group” refers to an ion or atom orcollection of atoms that may be ionic having a nucleophilic center,i.e., a center that is seeking an electrophilic center or with anelectrophile.

A “physiologically cleavable” or “hydrolyzable” bond is a bond thatreacts with water (i.e., is hydrolyzed) under physiological conditions.The tendency of a bond to hydrolyze in water will depend not only on thegeneral type of linkage connecting two central atoms but also on thesubstituents attached to these central atoms. Appropriate hydrolyticallyunstable or weak linkages include but are not limited to carboxylateester, phosphate ester, anhydrides, acetals, ketals, acyloxyalkyl ether,imines, orthoesters, peptides and oligonucleotides.

An “enzymatically degradable linkage” means a linkage that is subject todegradation by one or more enzymes.

A “hydrolytically stable” linkage or bond refers to a chemical bond,typically a covalent bond, that is substantially stable in water, thatis to say, does not undergo hydrolysis under physiological conditions toany appreciable extent over an extended period of time. Examples ofhydrolytically stable linkages include, but are not limited to, thefollowing: carbon-carbon bonds (e.g., in aliphatic chains), ethers,amides, urethanes, and the like. Generally, a hydrolytically stablelinkage is one that exhibits a rate of hydrolysis of less than about1-2% per day under physiological conditions. Hydrolysis rates ofrepresentative chemical bonds can be found in most standard chemistrytextbooks.

“Pharmaceutically acceptable excipient” refers to an excipient that mayoptionally be included in the compositions of the invention and thatcauses no significant adverse toxicological effects to the patient.

“Therapeutically effective amount” is used herein to mean the amount ofa polymer-Factor IX moiety conjugate that is needed to provide a desiredlevel of the conjugate (or corresponding unconjugated Factor IX moiety)in the bloodstream or in the target tissue. The precise amount willdepend upon numerous factors, e.g., the particular Factor IX moiety, thecomponents and physical characteristics of the therapeutic composition,intended patient population, mode of delivery, individual patientconsiderations, and the like, and can readily be determined by oneskilled in the art, based upon the information provided herein.

“Multi-functional” means a polymer having three or more functionalgroups contained therein, where the functional groups may be the same ordifferent. Multi-functional polymeric reagents will typically containfrom about 3-100 functional groups, or from 3-50 functional groups, orfrom 3-25 functional groups, or from 3-15 functional groups, or from 3to 10 functional groups, or will contain 3, 4, 5, 6, 7, 8, 9 or 10functional groups within the polymer backbone.

The term “Factor IX moiety,” as used herein, refers to a moiety havingFactor IX activity. The Factor IX moiety will also have at least oneelectrophilic group or nucleophilic group suited for reaction with apolymeric reagent. Typically, although not necessarily, the Factor IXmoiety is a protein. In addition, the term “Factor IX moiety”encompasses both the Factor IX moiety prior to conjugation as well asthe Factor IX moiety residue following conjugation. As will be explainedin further detail below, one of ordinary skill in the art can determinewhether any given moiety has Factor IX activity. A protein comprising anamino acid sequence corresponding to SEQ ID NO: 1 is a Factor IX moiety,as well as any protein or polypeptide substantially homologous thereto,whose biological properties result in the activity of Factor IX. As usedherein, the term “Factor IX moiety” includes proteins modifieddeliberately, as for example, by site directed mutagenesis oraccidentally through mutations. The term “Factor IX moiety” alsoincludes derivatives having from 1 to 6 additional glycosylation sites,derivatives having at least one additional amino acid at the carboxyterminal end of the protein wherein the additional amino acid(s)includes at least one glycosylation site, and derivatives having anamino acid sequence which includes at least one glycosylation site.

The term “substantially homologous” means that a particular subjectsequence, for example, a mutant sequence, varies from a referencesequence by one or more substitutions, deletions, or additions, the neteffect of which does not result in an adverse functional dissimilaritybetween the reference and subject sequences. For purposes of the presentinvention, sequences having greater than 95 percent homology, equivalentbiological properties (although potentiality different degrees ofactivity), and equivalent expression characteristics are consideredsubstantially homologous. For purposes of determining homology,truncation of the mature sequence should be disregarded. Sequenceshaving lesser degrees of homology, comparable bioactivity, andequivalent expression characteristics are considered substantialequivalents. Exemplary Factor IX moieties for use herein include thoseproteins having a sequence that is substantially homologous to SEQ IDNO: 1.

The term “fragment” means any protein or polypeptide having the aminoacid sequence of a portion of a Factor IX moiety that retains somedegree of Factor IX activity. Fragments include proteins or polypeptidesproduced by proteolytic degradation of the Factor IX protein or producedby chemical synthesis by methods routine in the art. Determining whethera particular fragment has the biological activity of Factor IX cancarried out by conventional, well known tests utilized for such purposeson one or more species of mammals. An appropriate test which can beutilized to demonstrate such biological activity is described herein.

A “deletion variant” of a Factor IX moiety is peptide or protein inwhich one amino acid residue of the Factor IX moiety has been deletedand the amino acid residues preceding and following the deleted aminoacid residue are connected via an amide bond (except in instances wherethe deleted amino acid residue was located on a terminus of the peptideor protein). Deletion variants include instances where only a singleamino acid residue has been deleted, as well as instances where twoamino acids are deleted, three amino acids are deleted, four amino acidsare deleted, and so forth. Each deletion variant must, however, retainsome degree of Factor IX activity.

A “substitution variant” of a Factor IX moiety is peptide or protein inwhich one amino acid residue of the Factor IX moiety has been deletedand a different amino acid residue has taken its place. Substitutionvariants include instances where only a single amino acid residue hasbeen substituted, as well as instances where two amino acids aresubstituted, three amino acids are substituted, four amino acids aresubstituted, and so forth. Each substitution variant must, however, havesome degree of Factor IX activity.

An “addition variant” of a Factor IX moiety is peptide or protein inwhich one amino acid residue of the Factor IX moiety has been added intoan amino acid sequence and adjacent amino acid residues are attached tothe added amino acid residue by way of amide bonds (except in instanceswhere the added amino acid residue is located on a terminus of thepeptide or protein, wherein only a single amide bond attaches the addedamino acid residue). Addition variants include instances where only asingle amino acid residue has been added, as well as instances where twoamino acids are added, three amino acids are added, four amino acids areadded, and so forth. Each addition variant must, however, have somedegree of Factor IX activity.

The term “patient,” refers to a living organism suffering from or proneto a condition that can be prevented or treated by administration of anactive agent (e.g., conjugate), and includes both humans and animals.

“Optional” or “optionally” means that the subsequently describedcircumstance may or may not occur, so that the description includesinstances where the circumstance occurs and instances where it does not.

“Substantially” (unless specifically defined for a particular contextelsewhere or the context clearly dictates otherwise) means nearlytotally or completely, for instance, satisfying one or more of thefollowing: greater than 50%, 51% or greater, 75% or greater, 80% orgreater, 90% or greater, and 95% or greater of the condition.

Unless the context clearly dictates otherwise, when the term “about”precedes a numerical value, the numerical value is understood tomean±10% of the stated numerical value.

Amino acid residues in peptides are abbreviated as follows:Phenylalanine is Phe or F; Leucine is Leu or L; Isoleucine is Ile or I;Methionine is Met or M; Valine is Val or V; Serine is Ser or S; Prolineis Pro or P; Threonine is Thr or T; Alanine is Ala or A; Tyrosine is Tyror Y; Histidine is H is or H; Glutamine is Gln or Q; Asparagine is Asnor N; Lysine is Lys or K; Aspartic Acid is Asp or D; Glutamic Acid isGlu or E; Cysteine is Cys or C; Tryptophan is Trp or W; Arginine is Argor R; and Glycine is Gly or G.

Turning to one or more embodiments of the invention, a conjugate isprovided, the conjugate comprising a Factor IX moiety covalentlyattached, either directly or through a spacer moiety comprised of one ormore atoms, to a water-soluble polymer. The conjugates of the inventionwill have one or more of the following features.

The Factor IX Moiety

As previously stated, the term “Factor IX moiety” shall include theFactor IX moiety prior to conjugation as well as to the Factor IX moietyfollowing attachment to a water-soluble polymer. It is understood,however, that when the Factor IX moiety is attached to a nonpeptidicwater-soluble polymer, the Factor IX moiety is slightly altered due tothe presence of one or more covalent bonds associated with linkage tothe polymer (or spacer moiety that is attached to the polymer). Often,this slightly altered form of the Factor IX moiety attached to anothermolecule is referred to a “residue” of the Factor IX moiety.

The Factor IX moiety can be derived from either non-recombinant methodsor from recombinant methods and the invention is not limited in thisregard. In addition, the Factor IX moiety can be derived from humansources or from animal sources.

The Factor IX moiety can be derived non-recombinantly. For example, theFactor IX moiety can be obtained from blood-derived sources. Inparticular, Factor DC can be fractionated from human plasma usingprecipitation and centrifugation techniques known to those of ordinaryskill in the art. See, for example, Wickerhauser (1976) Transfusion16(4):345-350 and Slichter et al. (1976) Transfusion 16(6):616-626.Factor IX can also be isolated from human granulocytes. See Szmitkoskiet al. (1977) Haematologia (Budap.) 11(1-2):177-187.

The Factor IX moiety can be derived from recombinant methods. Forexample, the cDNA coding for native Factor IX, which is a Factor IXmoiety, has been isolated, characterized, and cloned into expressionvectors. See, e.g., Choo et al. (1982) “Molecular Cloning of the Genefor Human Anti-hemophilic Factor IX,” Nature, Vol. 299: 178-180, andKurachi et al. (1982) “Isolation and Characterization of a cDNA Codingfor Human Factor IX,” Proc. Natl. Acad. Sci. U.S.A., Vol. 79: 6461-65.

Once expressed, native Factor IX is a single chain glycoprotein of about55,000 Daltons. It can structurally be considered as having fourdomains: the Gla or gamma carboxyglutamate-rich domain; the EGF-likeregions; the activation peptide; and the active site. The expressedamino acid sequence is provided as SEQ ID NO: 1. Unless specificallynoted, all assignments of a numeric location of an amino acid residue asprovided herein are based on SEQ ID NO: 1.

Exemplary recombinant methods used to prepare a Factor IX moiety(whether native Factor IX or a different protein having Factor IXactivity) can be briefly described. Such methods involve constructingthe nucleic acid encoding the desired polypeptide or fragment, cloningthe nucleic acid into an expression vector, transforming a host cell(e.g., plant, bacteria such as E. coli, yeast such as Saccharomycescerevisiae, or mammalian cell such as Chinese hamster ovary cell or babyhamster kidney cell), and expressing the nucleic acid to produce thedesired polypeptide or fragment. The expression can occur via exogenousexpression (when the host cell naturally contains the desired geneticcoding) or via endogenous expression. Methods for producing andexpressing recombinant polypeptides in vitro and in prokaryotic andeukaryotic host cells are known to those of ordinary skill in the art.See, for example, U.S. Pat. No. 4,868,122.

To facilitate identification and purification of the recombinantpolypeptide, nucleic acid sequences that encode for an epitope tag orother affinity binding sequence can be inserted or added in-frame withthe coding sequence, thereby producing a fusion protein comprised of thedesired polypeptide and a polypeptide suited for binding. Fusionproteins can be identified and purified by first running a mixturecontaining the fusion protein through an affinity column bearing bindingmoieties (e.g., antibodies) directed against the epitope tag or otherbinding sequence in the fusion proteins, thereby binding the fusionprotein within the column. Thereafter, the fusion protein can berecovered by washing the column with the appropriate solution (e.g.,acid) to release the bound fusion protein. The recombinant polypeptidecan also be identified and purified by lysing the host cells, separatingthe polypeptide, e.g., by size exclusion chromatography, and collectingthe polypeptide. These and other methods for identifying and purifyingrecombinant polypeptides are known to those of ordinary skill in theart. In one or more embodiments of the present invention, however, it ispreferred that the Factor IX moiety is not in the form of a fusionprotein.

Depending on the system used to express proteins having Factor IXactivity, the Factor IX moiety can be unglycosylated or glycosylated andeither may be used. That is, the Factor IX moiety can be unglycosylatedor the Factor IX moiety can be glycosylated. In one or more embodimentsof the invention, it is preferred that the Factor IX moiety isglycosylated.

The moiety having Factor IX activity can advantageously be modified toinclude one or more amino acid residues such as, for example, lysine,cysteine and/or arginine, in order to provide facile attachment of apolymer to an atom within an amino acid. In addition, the Factor IXmoiety can be modified to include a non-naturally occurring amino acidresidue. Techniques for adding amino acid residues and non-naturallyoccurring amino acid residues are well known to those of ordinary skillin the art. Reference is made to J. March, Advanced Organic ChemistryReactions Mechanisms and Structure, 4th Ed. (New York:Wiley-Interscience, 1992).

In addition, the Factor IX moiety can advantageously be modified toinclude attachment of a functional group (other than through addition ofa functional group-containing amino acid residue). For example, theFactor IX moiety can be modified to include a thiol group. In addition,the Factor IX moiety can be modified to include an N-terminal alphacarbon. In addition, the Factor IX moiety can be modified to include oneor more carbohydrate moieties. Factor DC moieties modified to contain anaminoxy, aldehyde or other functional group can also be used.

Nonlimiting examples of Factor IX moieties include the following: FactorIX; Factor IXa; truncated versions of Factor IX; hybrid proteins, andpeptide mimetics having Factor IX activity. Biologically activefragments, deletion variants, substitution variants or addition variantsof any of the foregoing that maintain at least some degree of Factor IXactivity can also serve as a Factor IX moiety.

For any given moiety, it is possible to determine whether that moietyhas Factor IX activity. For example, several animal lines have beenintentionally bred with the genetic mutation for hemophilia such that ananimal produced from such a line has very low and insufficient levels ofFactor IX. Such lines are available from a variety of sources such as,without limitation, the Division of Laboratories and Research, New YorkDepartment of Public Health, Albany, N.Y. and the Department ofPathology, University of North Carolina, Chapel Hill, N.C. Both of thesesources, for example, provide canines suffering from canine hemophiliaB. In order to test the Factor IX activity of any given moiety inquestion, the moiety is injected into the diseased animal, a small cutmade and bleeding time compared to a healthy control. Another methoduseful for determining Factor IX activity is to determine cofactor andprocoagulant activity. See, for example, Mertens et al. (1993) Brit. J.Haematol. 85:133-42. Other methods known to those of ordinary skill inthe art can also be used to determine whether a given moiety has FactorIX activity. Such methods are useful for determining the Factor IXactivity of both a proposed Factor IX moiety as well as thecorresponding polymer-Factor IX moiety conjugate.

The Water-Soluble Polymer

As previously discussed, each conjugate comprises a Factor IX moietyattached to a water-soluble polymer. With respect to the water-solublepolymer, the water-soluble polymer is nonpeptidic, nontoxic,non-naturally occurring and biocompatible. With respect tobiocompatibility, a substance is considered biocompatible if thebeneficial effects associated with use of the substance alone or withanother substance (e.g., an active agent such a Factor IX moiety) inconnection with living tissues (e.g., administration to a patient)outweighs any deleterious effects as evaluated by a clinician, e.g., aphysician. With respect to non-immunogenicity, a substance is considerednonimmunogenic if the intended use of the substance in vivo does notproduce an undesired immune response (e.g., the formation of antibodies)or, if an immune response is produced, that such a response is notdeemed clinically significant or important as evaluated by a clinician.It is particularly preferred that the water-soluble polymer isbiocompatible and nonimmunogenic.

Further the polymer is typically characterized as having from 2 to about300 termini. Examples of such polymers include, but are not limited to,poly(alkylene glycols) such as polyethylene glycol (PEG), poly(propyleneglycol) (“PPG”), copolymers of ethylene glycol and propylene glycol andthe like, poly(oxyethylated polyol), poly(olefinic alcohol),poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide),poly(hydroxyalkylmethacrylate), poly(saccharides), poly(α-hydroxy acid),poly(vinyl alcohol), polyphosphazene, polyoxazoline,poly(N-acryloylmorpholine), and combinations of any of the foregoing.

The polymer is not limited in a particular structure and can be linear(e.g., alkoxy PEG or bifunctional PEG), or non-linear such as branched,forked, multi-armed (e.g., PEGs attached to a polyol core), anddendritic. Moreover, the internal structure of the polymer can beorganized in any number of different patterns and can be selected fromthe group consisting of homopolymer, alternating copolymer, randomcopolymer, block copolymer, alternating tripolymer, random tripolymer,and block tripolymer.

Typically, activated PEG and other activated water-soluble polymers(i.e., polymeric reagents) are activated with a suitable activatinggroup appropriate for coupling to a desired site on the Factor IXmoiety. Thus, a polymeric reagent will possess a reactive group forreaction with the Factor IX moiety. Representative polymeric reagentsand methods for conjugating these polymers to an active moiety are knownin the art and further described in Zalipsky, S., et al., “Use ofFunctionalized Poly(Ethylene Glycols) for Modification of Polypeptides”in Polyethylene Glycol Chemistry: Biotechnical and BiomedicalApplications, J. M. Harris, Plenus Press, New York (1992), and inZalipsky (1995) Advanced Drug Reviews 16:157-182.

Typically, the weight-average molecular weight of the water-solublepolymer in the conjugate is from about 100 Daltons to about 150,000Daltons. Exemplary ranges, however, include weight-average molecularweights in the range of greater than 5,000 Daltons to about 100,000Daltons, in the range of from about 6,000 Daltons to about 90,000Daltons, in the range of from about 10,000 Daltons to about 85,000Daltons, in the range of greater than 10,000 Daltons to about 85,000Daltons, in the range of from about 20,000 Daltons to about 85,000Daltons, in the range of from about 53,000 Daltons to about 85,000Daltons, in the range of from about 25,000 Daltons to about 120,000Daltons, in the range of from about 29,000 Daltons to about 120,000Daltons, in the range of from about 35,000 Daltons to about 120,000Daltons, and in the range of from about 40,000 Daltons to about 120,000Daltons. For any given water-soluble polymer, PEGs having a molecularweight in one or more of these ranges are preferred.

Exemplary weight-average molecular weights for the water-soluble polymerinclude about 100 Daltons, about 200 Daltons, about 300 Daltons, about400 Daltons, about 500 Daltons, about 600 Daltons, about 700 Daltons,about 750 Daltons, about 800 Daltons, about 900 Daltons, about 1,000Daltons, about 1,500 Daltons, about 2,000 Daltons, about 2,200 Daltons,about 2,500 Daltons, about 3,000 Daltons, about 4,000 Daltons, about4,400 Daltons, about 4,500 Daltons, about 5,000 Daltons, about 5,500Daltons, about 6,000 Daltons, about 7,000 Daltons, about 7,500 Daltons,about 8,000 Daltons, about 9,000 Daltons, about 10,000 Daltons, about11,000 Daltons, about 12,000 Daltons, about 13,000 Daltons, about 14,000Daltons, about 15,000 Daltons, about 20,000 Daltons, about 22,500Daltons, about 25,000 Daltons, about 30,000 Daltons, about 35,000Daltons, about 40,000 Daltons, about 45,000 Daltons, about 50,000Daltons, about 55,000 Daltons, about 60,000 Daltons, about 65,000Daltons, about 70,000 Daltons, and about 75,000 Daltons. Branchedversions of the water-soluble polymer (e.g., a branched 40,000 Daltonwater-soluble polymer comprised of two 20,000 Dalton polymers) having atotal molecular weight of any of the foregoing can also be used. In oneor more embodiments, the conjugate will not have any PEG moietiesattached, either directly or indirectly, with a PEG having aweight-average molecular weight of less than about 6,000 Daltons.

When used as the polymer, PEGs will typically comprise a number of(OCH₂CH₂) monomers [or (CH₂CH₂O) monomers, depending on how the PEG isdefined]. As used throughout the description, the number of repeatingunits is identified by the subscript “n” in “(OCH₂CH₂)_(n).” Thus, thevalue of (n) typically falls within one or more of the following ranges:from 2 to about 3400, from about 100 to about 2300, from about 100 toabout 2270, from about 136 to about 2050, from about 225 to about 1930,from about 450 to about 1930, from about 1200 to about 1930, from about568 to about 2727, from about 660 to about 2730, from about 795 to about2730, from about 795 to about 2730, from about 909 to about 2730, andfrom about 1,200 to about 1,900. For any given polymer in which themolecular weight is known, it is possible to determine the number ofrepeating units (i.e., “n”) by dividing the total weight-averagemolecular weight of the polymer by the molecular weight of the repeatingmonomer.

With regard to the molecular weight of the water-soluble polymer, in ormore embodiments of the invention, a conjugate is provided, theconjugate comprising a Factor IX moiety covalently attached, eitherdirectly or through a spacer moiety comprised of one or more atoms, to awater-soluble polymer, wherein the molecular weight of the water-solublepolymer is greater than 5,000 Daltons and less than about 150,000Daltons.

One particularly preferred polymer for use in the invention is anend-capped polymer, that is, a polymer having at least one terminuscapped with a relatively inert group, such as a lower C₁₋₆ alkoxy group,although a hydroxyl group can also be used. When the polymer is PEG, forexample, it is preferred to use a methoxy-PEG (commonly referred to asmPEG), which is a linear form of PEG wherein one terminus of the polymerhas a methoxy (—OCH₃) group, while the other terminus is a hydroxyl orother functional group that can be optionally chemically modified.

In one form useful in the present invention, free or unbound PEG is alinear polymer terminated at each end with hydroxyl groups:

HO—CH₂CH₂O—(CH₂CH₂O)_(n)—CH₂CH₂—OH,

wherein (n) typically ranges from zero to about 4,000.

The above polymer, alpha-, omega-dihydroxylpoly(ethylene glycol), can berepresented in brief form as HO-PEG-OH where it is understood that the-PEG-symbol can represent the following structural unit:

—CH₂CH₂O—(CH₂CH₂O)_(n)—CH₂CH₂—,

wherein (n) is as defined as above.

Another type of PEG useful in the present invention is methoxy-PEG-OH,or mPEG in brief, in which one terminus is the relatively inert methoxygroup, while the other terminus is a hydroxyl group. The structure ofmPEG is given below.

CH₃O—CH₂CH₂O—(CH₂CH₂O), —CH₂CH₂—OH

wherein (n) is as described above.

Multi-armed or branched PEG molecules, such as those described in U.S.Pat. No. 5,932,462, can also be used as the PEG polymer. For example,PEG can have the structure:

wherein:

poly_(a) and poly_(b) are PEG backbones (either the same or different),such as methoxy poly(ethylene glycol);

R″ is a non-reactive moiety, such as H, methyl or a PEG backbone; and

P and Q are non-reactive linkages. In a one or more embodiments, thebranched PEG polymer is methoxy poly(ethylene glycol) disubstitutedlysine. Depending on the specific Factor IX moiety used, the reactiveester functional group of the disubstituted lysine may be furthermodified to form a functional group suitable for reaction with thetarget group within the Factor IX moiety.

In addition, the PEG can comprise a forked PEG. An example of a forkedPEG is represented by the following structure:

wherein X is a spacer moiety of one or more atoms and each Z is anactivated terminal group linked to CH by a chain of atoms of definedlength. International Application No. PCT/US99/05333, discloses variousforked PEG structures capable of use in one or more embodiments of thepresent invention. The chain of atoms linking the Z functional groups tothe branching carbon atom serve as a tethering group and may comprise,for example, alkyl chains, ether chains, ester chains, amide chains andcombinations thereof.

The PEG polymer may comprise a pendant PEG molecule having reactivegroups, such as carboxyl, covalently attached along the length of thePEG rather than at the end of the PEG chain. The pendant reactive groupscan be attached to the PEG directly or through a spacer moiety, such asan alkylene group.

In addition to the above-described forms of PEG, the polymer can also beprepared with one or more weak or degradable linkages (such as ahydrolytically degradable linkage) in the polymer, including any of theabove described polymers. For example, PEG can be prepared with esterlinkages in the polymer that are subject to hydrolysis. As shown below,this hydrolysis results in cleavage of the polymer into fragments oflower molecular weight:

—PEG-CO₂—PEG-+H₂O→-PEG-CO₂H+HO-PEG-

Other hydrolytically degradable linkages, useful as a degradable linkagewithin a polymer backbone, include: carbonate linkages; imine linkagesresulting, for example, from reaction of an amine and an aldehyde (see,e.g., Ouchi et al. (1997) Polymer Preprints 38(1):582-3); phosphateester linkages formed, for example, by reacting an alcohol with aphosphate group; hydrazone linkages which are typically formed byreaction of a hydrazide and an aldehyde; acetal linkages that aretypically formed by reaction between an aldehyde and an alcohol;orthoester linkages that are, for example, formed by reaction between aformate and an alcohol; amide linkages formed by an amine group, e.g.,at an end of a polymer such as PEG, and a carboxyl group of another PEGchain; urethane linkages formed from reaction of, e.g., a PEG with aterminal isocyanate group and a PEG alcohol; peptide linkages formed byan amine group, e.g., at an end of a polymer such as PEG, and a carboxylgroup of a peptide; and oligonucleotide linkages formed by, for example,a phosphoramidite group, e.g., at the end of a polymer, and a 5′hydroxyl group of an oligonucleotide.

Such optional features of the polymer conjugate, i.e., the introductionof one or more degradable linkages into the polymer chain, may providefor additional control over the final desired pharmacological propertiesof the conjugate upon administration. For example, a large andrelatively inert conjugate (e.g., having one or more high molecularweight PEG chains attached to a Factor IX moiety, for example, one ormore PEG chains having a molecular weight greater than about 10,000,wherein the conjugate possesses essentially no bioactivity) may beadministered, which is hydrolyzed to generate a bioactive conjugatepossessing a portion of the original PEG chain. In this way, theproperties of the conjugate can be more effectively tailored to balancethe bioactivity of the conjugate over time.

Those of ordinary skill in the art will recognize that the foregoingdiscussion concerning substantially water-soluble polymer segments is byno means exhaustive and is merely illustrative, and that all polymericmaterials having the qualities described above are contemplated. As usedherein, the term “polymeric reagent” generally refers to an entiremolecule, which can comprise a water-soluble polymer segment and afunctional group.

Conjugates

As described above, a conjugate of the invention comprises awater-soluble polymer covalently attached (either directly or through aspacer moiety) to a Factor IX moiety. Typically, for any givenconjugate, there will be one to four water-soluble polymers covalentlyattached to a Factor IX moiety (wherein for each water-soluble polymer,the water soluble polymer can be attached either directly to the FactorIX moiety or through a spacer moiety). In some instances, however, theconjugate may have 1, 2, 3, 4, 5, 6, 7, 8 or more water-soluble polymersindividually attached to a Factor IX moiety. In addition, the conjugatemay include not more than 8 water-soluble polymers individually attachedto a Factor IX moiety, not more than 7 water-soluble polymersindividually attached to a Factor IX moiety, not more than 6water-soluble polymers individually attached to a Factor IX moiety, notmore than 5 water-soluble polymers individually attached to a Factor IXmoiety, not more than 4 water-soluble polymers individually attached toa Factor IX moiety, not more than 3 water-soluble polymers individuallyattached to a Factor IX moiety, and not more than 2 water-solublepolymers individually attached to a Factor IX moiety.

The particular linkage between the Factor IX moiety and the polymer (orthe spacer moiety that is attached to the polymer) depends on a numberof factors. Such factors include, for example, the particular linkagechemistry employed, the particular Factor IX moiety, the availablefunctional groups within the Factor IX moiety (either for attachment toa polymer or conversion to a suitable attachment site), the possiblepresence of additional reactive functional groups within the Factor IXmoiety, and the like.

In one or more embodiments of the invention, the linkage between theFactor IX moiety and the polymer (or the spacer moiety that is attachedto the polymer) is a hydrolytically stable linkage, such as an amide,urethane (also known as carbamate), amine, thioether (also known assulfide), or urea (also known as carbamide). In one or more embodiments,the linkage does not result from reaction of the polymeric reagentbearing triazine, acetyl, hydrazine, diazonium, amino, or succinimidylester functional group with the Factor IX moiety. In some cases, it ispreferred that the linkage is not a carbamate linkage and not acarbamide linkage, and furthermore, that no linkage is formed based onthe reaction of a polymer derivative bearing an isocyanate orisothiocyanate species to a Factor IX moiety. Again, a preferredhydrolytically stable linkage is an amide. An amide can be readilyprepared by reaction of a carboxyl group contained within the Factor IXmoiety (e.g., the terminal carboxyl of a peptidic moiety having FactorIX activity) with an amino-terminated polymer.

In one or more embodiments of the invention, the linkage between theFactor IX moiety and the polymer (or the spacer moiety that is attachedto the polymer) is a degradable linkage. In this way, the linkage of thewater-soluble polymer (and any spacer moiety) is “cleavable.” That is,the water-soluble polymer (and any spacer moiety) cleaves (eitherthrough hydrolysis, enzymatic processes, or otherwise), therebyresulting in the native or unconjugated Factor IX moiety. Preferably,cleavable linkages result in the polymer (and any spacer moiety)detaching from the Factor IX moiety in vivo without leaving any fragmentof the water-soluble polymer (and any spacer moiety). Exemplarydegradable linkages include carbonate, carboxylate ester, phosphateester, thiolester, anhydrides, acetals, ketals, acyloxyalkyl ether,imines, and orthoesters. Such linkages can be readily prepared byappropriate modification of either the Factor IX moiety (e.g., thecarboxyl group C terminus of the protein or a side chain hydroxyl groupof an amino acid such as serine or threonine contained within theprotein) and/or the polymeric reagent using coupling methods commonlyemployed in the art. Most preferred, however, are hydrolyzable linkagesthat are readily formed by reaction of a suitably activated polymer witha non-modified functional group contained within the moiety havingFactor IX activity.

With regard to linkages, in one more embodiments of the invention, aconjugate is provided, comprising a Factor IX moiety covalently attachedat an amino acid residue, either directly or through a spacer moietycomprised of one or more atoms, to a water-soluble polymer, wherein theamino acid residue is not attached, either directly or though the spacermoiety, via a CH₂—C(O)—O—, —N(H)—C(O)CH₂—O—, —C(O)—N(H)—,—N(H)—C(O)—CH₂—O—, —C(O)—CH₂—O—, —C(O)—CH₂—CH₂—C(O)—O—, diazo, ortriazine linkage.

The conjugates (as opposed to an unconjugated Factor IX moiety) may ormay not possess a measurable degree of Factor IX activity. That is tosay, a conjugate in accordance with the invention will possessesanywhere from about 0% to about 100% or more of the bioactivity of theunmodified parent Factor IX moiety. Preferably, compounds possessinglittle or no Factor IX activity typically contain a hydrolyzable linkageconnecting the polymer to the moiety, so that regardless of the lack ofactivity in the conjugate, the active parent molecule (or a derivativethereof having Factor IX activity) is released upon aqueous-inducedcleavage of the linkage. Such activity may be determined using asuitable in-vivo or in-vitro model, depending upon the known activity ofthe particular moiety having Factor IX activity employed.

Optimally, cleavage of each water-soluble polymer portion is facilitatedthrough the use of physiologically cleavable and/or enzymaticallydegradable linkages such as urethane, amide, carbonate orester-containing linkages. In this way, clearance of the conjugate [viacleavage of individual water-soluble polymer(s)] can be modulated byselecting the polymer molecular size and the type functional group thatwould provide the desired clearance properties. One of ordinary skill inthe art can determine the proper molecular size of the polymer as wellas the cleavable functional group. For example, one of ordinary skill inthe art, using routine experimentation, can determine a proper molecularsize and cleavable functional group by first preparing a variety ofpolymer-Factor IX conjugates with different polymer weights andcleavable functional groups, and then obtaining the clearance profilefor each conjugate by administering the conjugate to a patient andtaking periodic blood and/or urine sampling. Once a series of clearanceprofiles have been obtained for each tested conjugate, a conjugatehaving the desired clearance can be identified.

For conjugates possessing a hydrolytically stable linkage that couplesthe Factor IX moiety to the polymer, the conjugate will typicallypossess a measurable degree of Factor IX activity. For instance, suchconjugates are typically characterized as having a bioactivitysatisfying one or more of the following percentages relative to that ofthe unconjugated Factor IX moiety: at least about 2%, at least about 5%,at least about 10%, at least about 15%, at least about 25%, at leastabout 30%, at least about 40%, at least about 50%, at least about 60%,at least about 80%, at least about 85%, at least about 90%, at leastabout 95%, at least about 97%, at least about 100%, and more than 105%(when measured in a suitable model, such as those presented here and/orwell known in the art). Preferably, conjugates having a hydrolyticallystable linkage (e.g., an amide linkage) will possess at least somedegree of the bioactivity of the unmodified parent Factor IX moiety.

Exemplary conjugates will now be described. The Factor IX moiety isexpected to share (at least in part) an amino acid sequence similar orrelated to native Factor IX. Thus, while reference will be made tospecific locations or atoms within the native Factor IX protein, such areference is for convenience only and one having ordinary skill in theart will be able to readily determine the corresponding location or atomin other moieties having Factor IX activity. In particular, thedescription provided herein for native Factor IX is often applicable toFactor IXa, as well as fragments, deletion variants, substitutionvariants or addition variants of any of the foregoing.

Amino groups on Factor IX moieties can provide a point of attachmentbetween the Factor IX moiety and the water-soluble polymer. NativeFactor IX comprises 27 lysine residues, each having an ε-amino groupthat may be available for conjugation, as well as one amino terminus.Thus, exemplary attachment points of such Factor IX moieties includeattachment at an amino acid (through the amine-containing side chain oflysine) at any one or more of positions 39, 45, 51, 68, 89, 109, 127,137, 146, 168, 189, 234, 247, 260, 274, 293, 311, 339, 347, 362, 387,438, 440, 446, 455, 457, and 459. Further, the N-terminal amine of anyprotein having Factor IX activity can also serve as a point ofattachment.

There are a number of examples of suitable water-soluble polymericreagents useful for forming covalent linkages with available amines of aFactor IX moiety. Specific examples, along with the correspondingconjugates, are provided in Table 1, below. In the table, the variable(n) represents the number of repeating monomeric units and “—NH—F9”represents the Factor IX moiety following conjugation to thewater-soluble polymer. While each polymeric portion [e.g., (OCH₂CH₂)_(n)or (CH₂CH₂O)_(n)] presented in Table 1 terminates in a “CH₃” group,other groups (such as H and benzyl) can be substituted therefor.

TABLE 1 Amine-Specific Polymeric Reagents and the Factor IX MoietyConjugate Formed Therefrom Polymeric Reagent Corresponding Conjugate

H₃C—(OCH₂CH₂)_(n)—O—CH₂CH₂—CH₂—NH—F9 Secondary Amine Linkage

H₃C—(OCH₂CH₂)_(n)—O—CH₂CH₂CH₂—CH₂—NH—F9 Secondary Amine Linkage

H₃C—(OCH₂CH₂)_(n)—O—CH₂CH₂—NH—F9 Secondary Amine Linkage

H₃CO—(CH₂CH₂O)_(n)—CH₂CH₂—NH—F9 Secondary Amine Linkage

Conjugation of a polymeric reagent to an amine group of a Factor IXmoiety can be accomplished by a variety of techniques. In one approach,a Factor IX moiety can be conjugated to a polymeric reagentfunctionalized with a succinimidyl derivative (or other activated estergroup, wherein approaches similar to those described for a succinimidylderivative can be used for other activated ester group-containingpolymeric reagents). In this approach, the polymeric reagent bearing asuccinimidyl group can be attached to the Factor IX moiety in aqueousmedia at a pH of 7.0 to 9.0, although different reaction conditions(e.g., a lower pH such as 6 to 7, or different temperatures and/or lessthan 15° C.) can result in the attachment of a polymer to a differentlocation on the Factor IX moiety. In addition, an amide linkage can beformed by reacting an amine-terminated non-peptidic, water-solublepolymer with a Factor IX moiety bearing an aldehyde or an activatedcarboxylic acid group.

An exemplary conjugate comprises the following structure

wherein:

(n) is an integer having a value of from 2 to 3400;

X is a spacer moiety, preferably one of methylene (“—CH₂—”), ethylene(“—CH₂CH₂—”) and propylene (“—CH₂CH₂CH₂—”);

R¹ is an organic radical, preferably H or methyl (“—CH₃”); and

F9 is a Factor IX moiety.

Typical of another approach useful for conjugating the Factor IX moietyto a polymeric reagent is the use of a reductive amination reaction toconjugate a primary amine of a Factor IX moiety with a polymerfunctionalized with a ketone, aldehyde or a hydrated form thereof (e.g.,ketone hydrate and aldehyde hydrate). In this approach, the primaryamine from the Factor IX moiety reacts with the carbonyl group of thealdehyde or ketone (or the corresponding hydroxy-containing group of ahydrated aldehyde or ketone), thereby forming a Schiff base. The Schiffbase, in turn, can then be reductively converted to a stable conjugatethrough use of a reducing agent such as sodium borohydride. Selectivereactions (e.g., at the N-terminus are possible) are possible,particularly with a polymer functionalized with a ketone or analpha-methyl branched aldehyde and/or under specific reaction conditions(e.g., reduced pH).

Carboxyl groups represent another functional group that can serve as apoint of attachment on the Factor IX moiety. Structurally, the conjugatewill comprise the following:

where F9 and the adjacent carbonyl group corresponds to thecarboxyl-containing Factor IX moiety, X is a spacer moiety, preferably aheteroatom selected from O, N(H), and S, and POLY is a water-solublepolymer such as PEG, optionally terminating in an end-capping moiety.

The C(O)—X linkage results from the reaction between a polymericderivative bearing a terminal functional group and a carboxyl-containingFactor IX moiety. As discussed above, the specific linkage will dependon the type of functional group utilized. If the polymer isend-functionalized or “activated” with a hydroxyl group, the resultinglinkage will be a carboxylic acid ester and X will be O. If the polymerbackbone is functionalized with a thiol group, the resulting linkagewill be a thioester and X will be S. When certain multi-arm, branched orforked polymers are employed, the C(O)X moiety, and in particular the Xmoiety, may be relatively more complex and may include a longer linkagestructure.

Polymeric reagents containing a hydrazide moiety are also useful forconjugation at a carbonyl. To the extent that the Factor IX moiety doesnot contain a carbonyl moiety, a carbonyl moiety can be introduced byreducing any carboxylic acids (e.g., the C-terminal carboxylic acid)and/or by providing glycosylated or glycated (wherein the added sugarshave a carbonyl moiety) versions of the Factor IX moiety. Specificexamples of polymeric reagents comprising a hydrazide moiety, along withthe corresponding conjugates, are provided in Table 2, below. Inaddition, any polymeric reagent comprising an activated ester (e.g., asuccinimidyl group) can be converted to contain a hydrazide moiety byreacting the polymeric reagent comprising the activated ester withhydrazine (NH₂—NH₂) or tert-butyl carbazate [NH₂NHCO₂C(CH₃)₃]. In thetable, the variable (n) represents the number of repeating monomericunits and “═C—F9” represents the Factor IX moiety following conjugationto the polymeric reagent. Optionally, the hydrazone linkage can bereduced using a suitable reducing agent. While each polymeric portion[e.g., (OCH₂CH₂)_(n) or (CH₂CH₂O)_(n)] presented in Table 1 terminatesin a “CH₃” group, other groups (such as H and benzyl) can be substitutedtherefor.

TABLE 2 Carboxyl-Specific Polymeric Reagents and the Factor IX MoietyConjugate Formed Therefrom Polymeric Reagent Corresponding Conjugate

Thiol groups contained within the Factor IX moiety can serve aseffective sites of attachment for the water-soluble polymer. Inparticular, cysteine residues provide thiol groups when the Factor IXmoiety is a protein. The thiol groups in such cysteine residues can bereacted with an activated PEG that is specific for reaction with thiolgroups, e.g., an N-maleimidyl polymer or other derivative, as describedin U.S. Pat. No. 5,739,208 and in International Patent Publication No.WO 01/62827.

While not wishing to be bound by theory, it is believed that all of thecysteine residues within Factor IX participate in disulfide bonding. Asa consequence, conjugation to a cysteine residue participating indisulfide bonding may disrupt the tertiary structure of Factor IX andpotentially significantly decrease its overall activity. Thus, to theextent that any particular Factor IX moiety lacks a thiol group ordisruption of disulfide bonds is to be avoided, it is possible to add acysteine residue to the Factor IX moiety using conventional synthetictechniques. See, for example, the procedure described in InternationalPatent Publication WO 90/12874 for adding cysteine residues, whereinsuch a procedure can be adapted for a Factor IX moiety. In addition,conventional genetic engineering processes can also be used to introducea cysteine residue into the Factor IX moiety.

Specific examples, along with the corresponding conjugates, are providedin Table 3, below. In the table, the variable (n) represents the numberof repeating monomeric units and “—S—F9” represents the Factor IX moietyfollowing conjugation to the water-soluble polymer. While each polymericportion [e.g., (OCH₂CH₂)_(n) or (CH₂CH₂O)_(n)] presented in Table 3terminates in a “CH₃” group, other groups (such as H and benzyl) can besubstituted therefor.

TABLE 3 Thiol-Specific Polymeric Reagents and the Factor IX MoietyConjugate Formed Therefrom Polymeric Reagent Corresponding Conjugate

Disulfide Linkages

H₃CO—(CH₂CH₂O)_(n)—CH₂CH₂CH₂CH₂—S—S—F9 Disulfide Linkage

F9—S—S—(CH₂)₂—(CH₂CH₂O)_(n)—(CH₂)₄—S—S—F9 Disulfide Linkages

With respect to conjugates formed from water-soluble polymers bearingone or more maleimide functional groups (regardless of whether themaleimide reacts with an amine or thiol group on the Factor IX moiety),the corresponding maleamic acid form(s) of the water-soluble polymer canalso react with the Factor IX moiety. Under certain conditions (e.g., apH of about 7-9 and in the presence of water), the maleimide ring will“open” to form the corresponding maleamic acid. The maleamic acid, inturn, can react with an amine or thiol group of a Factor IX moiety.Exemplary maleamic acid-based reactions are schematically shown below.POLY represents the water-soluble polymer, and F9 represents the FactorIX moiety.

A representative conjugate in accordance with the invention can have thefollowing structure:

POLY-L_(0.1)-C(O)Z—Y—S—S—F9

wherein POLY is a water-soluble polymer, L is an optional linker, Z is aheteroatom selected from the group consisting of O, NH, and S, and Y isselected from the group consisting of C₂₋₁₀ alkyl, C₂₋₁₀ substitutedalkyl, aryl, and substituted aryl, and F9 is a Factor IX moiety.Polymeric reagents that can be reacted with a Factor IX moiety andresult in this type of conjugate are described in U.S. PatentApplication Publication No. 2005/0014903.

With respect to polymeric reagents, those described here and elsewherecan be purchased from commercial sources (e.g., Nektar Therapeutics,Huntsville Ala.). In addition, methods for preparing the polymericreagents are described in the literature.

The attachment between the Factor IX moiety and water-soluble polymercan be direct, wherein no intervening atoms are located between theFactor IX moiety can the polymer, or indirect, wherein one or more atomsare located between the Factor IX moiety and polymer. With respect tothe indirect attachment, a “spacer moiety” serves as a link between theFactor IX moiety and the water-soluble polymer. The one or more atomsmaking up the spacer moiety can include one or more of carbon atoms,nitrogen atoms, sulfur atoms, oxygen atoms, and combinations thereof.The spacer moiety can comprise an amide, secondary amine, carbamate,thioether, and/or disulfide group. Nonlimiting examples of specificspacer moieties include those selected from the group consisting of —O—,—S—, —S—S—, —C(O)—, —C(O)—NH—, —NH—C(O)—NH—, —O—C(O)—NH—, —C(S)—, —CH₂—,—CH₂—CH₂—, —CH₂—CH₂—CH₂—, —CH₂—O—H₂—CH₂—CH₂—, —O—CH₂—, —CH₂—O—,—O—CH₂—CH₂—, —CH₂—O—CH₂—, —CH₂—CH₂—O—, —O—CH₂—CH₂—CH₂—, —CH₂—O—CH₂—CH₂—,—CH₂—CH₂—O—CH₂—, —CH₂—CH₂—CH₂—O—, —O—CH₂—CH₂—CH₂—CH₂—,—CH₂—O—CH₂—CH₂—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—CH₂—CH₂—O—CH₂—,—CH₂—CH₂—CH₂—CH₂—O—, —C(O)—NH—CH₂—, —C(O)—NH—CH₂—CH₂—,—CH₂—C(O)—NH—CH₂—, —CH₂—CH₂—C(O)—NH—, —C(O)—NH—CH₂—CH₂—CH₂—,—CH₂—C(O)—NH—CH₂—CH₂—, —CH₂—CH₂—C(O)—NH—CH₂—, —CH₂—CH₂—CH₂—C(O)—NH—,—C(O)—NH—CH₂—CH₂—CH₂—CH₂—, —CH₂—C(O)—NH—CH₂—CH₂—CH₂—,—CH₂—CH₂—C(O)—NH—CH₂—CH₂—, —CH₂—CH₂—CH₂—C(O)—NH—CH₂—,—CH₂—CH₂—CH₂—C(O)—NH—CH₂—CH₂—, —CH₂—CH₂—CH₂—CH₂—C(O)—NH—, —C(O)—O—CH₂—,—CH₂—C(O)—O—CH₂—, —CH₂—CH₂—C(O)—O—CH₂—, —C(O)—O—CH₂—CH₂—, —NH—C(O)—CH₂—,—CH₂—NH—C(O)—CH₂—, —CH₂—CH₂—NH—C(O)—CH₂—, —NH—C(O)—CH₂—CH₂—,—CH₂—NH—C(O)—CH₂—CH₂—, —CH₂—CH₂—NH—C(O)—CH₂—CH₂—, —C(O)—NH—CH₂—,—C(O)—NH—CH₂—CH₂—, —O—C(O)—NH—CH₂—, —O—C(O)—NH—CH₂—CH₂—, —NH—CH₂—,—NH—CH₂—CH₂—, —CH₂—NH—CH₂—, —CH₂—CH₂—NH—CH₂—, —C(O)—CH₂—,—C(O)—CH₂—CH₂—, —CH₂—C(O)—CH₂—, —CH₂—CH₂—C(O)—CH₂—,—CH₂—CH₂—C(O)—CH₂—CH₂—, —CH₂—CH₂—C(O)—,—CH₂—CH₂—CH₂—C(O)—NH—CH₂—CH₂—NH—, —CH₂—CH₂—CH₂—C(O)—NH—CH₂—CH₂—NH—C(O)—,—CH₂—CH₂—CH₂—C(O)—NH—CH₂—CH₂—NH—C(O)—CH₂—,—CH₂—CH₂—CH₂—C(O)—NH—CH₂—CH₂—NH—C(O)—CH₂—CH₂—,—O—C(O)—NH—[CH₂]_(h)—(OCH₂CH₂)_(j)—, bivalent cycloalkyl group, —O—,—S—, an amino acid, —N(R⁶)—, and combinations of two or more of any ofthe foregoing, wherein R⁶ is H or an organic radical selected from thegroup consisting of alkyl, substituted alkyl, alkenyl, substitutedalkenyl, alkynyl, substituted alkynyl, aryl and substituted aryl, (h) iszero to six, and (j) is zero to 20. Other specific spacer moieties havethe following structures: —C(O)—NH—(CH₂)₁₋₆—NH—C(O)—,—NH—C(O)—NH—(CH₂)₁₋₆—NH—C(O)—, and —O—C(O)—NH—(CH₂)₁₋₆—NH—C(O)—, whereinthe subscript values following each methylene indicate the number ofmethylenes contained in the structure, e.g., (CH₂)₁₋₆ means that thestructure can contain 1, 2, 3, 4, 5 or 6 methylenes. Additionally, anyof the above spacer moieties may further include an ethylene oxideoligomer chain comprising 1 to 20 ethylene oxide monomer units [i.e.,—(CH₂CH₂O)₁₋₂₀]. That is, the ethylene oxide oligomer chain can occurbefore or after the spacer moiety, and optionally in between any twoatoms of a spacer moiety comprised of two or more atoms. Also, theoligomer chain would not be considered part of the spacer moiety if theoligomer is adjacent to a polymer segment and merely represent anextension of the polymer segment. The spacer moiety does not includesugars or carbohydrates and it is preferred that the conjugate lackssubstantially any water-soluble polymers attached directly, or through aspacer moiety, to a sugar or carbohydrate that, in turn, is attached toa Factor IX moiety.

In some instances, the conjugate may only have a single water-solublepolymer associated with a single Factor IX moiety. As a consequence, itmay be desirous to have the water-soluble polymer be a non-linearwater-soluble polymer (and prepare the conjugate using a non-linearpolymeric reagent). A preferred non-linear water-soluble polymer is abranched water-soluble polymer, although multi-branched water-solublepolymers are included. By incorporating a branched water-solublepolymer, it is possible, for example, to double the effective molecularweight for each attachment site as compared to a single polymer.

Exemplary conjugates of the invention wherein the water-soluble polymeris in a branched form, include branched forms comprising a lysine-basedbranched polymer and a branched approach comprising the structure:

wherein each (n) is independently an integer having a value of from 2 to3400.

Exemplary conjugates of the invention comprise the following structure:

wherein:

each (n) is independently an integer having a value of from 2 to 3400;

X is spacer moiety;

(b) is an integer having a value 2 through 6;

(c) is an integer having a value 2 through 6;

R², in each occurrence, is independently H or lower alkyl; and

F9 is a Factor IX moiety.

An exemplary conjugate of the invention comprises the followingstructure:

wherein:

each (n) is independently an integer having a value of from 2 to 3400;and

F9 is a Factor IX moiety.

Another exemplary conjugate of the invention comprises the followingstructure:

wherein:

each (n) is independently an integer having a value of from 2 to 3400;

(a) is either zero or one;

X, when present, is a spacer moiety comprised of one or more atoms;

(b′) is zero or an integer having a value of one through ten;

(c) is an integer having a value of one through ten;

R², in each occurrence, is independently H or an organic radical;

R³, in each occurrence, is independently H or an organic radical; and

F9 is a Factor IX moiety.

An exemplary conjugates of the invention comprises the followingstructure:

wherein:

each (n) is independently an integer having a value of from 2 to 3400;and

F9 is a Factor IX moiety.

Compositions

The conjugates are typically part of a composition. Generally, thecomposition comprises a plurality of conjugates, preferably although notnecessarily, each having one, two, three or four water-soluble polymersseparately covalently attached (either directly or through a spacermoiety) to one Factor IX moiety. The compositions, however, can alsocomprise other conjugates having four, five, six, seven, eight or morepolymers attached to any given moiety having Factor IX activity. Inaddition, the invention includes instances wherein the compositioncomprises a plurality of conjugates, each conjugate comprising onewater-soluble polymer covalently attached to one Factor IX moiety, aswell as compositions comprising two, three, four, five, six, seven,eight, or more water-soluble polymers covalently attached to one FactorIX moiety.

In one or more embodiments of the invention, a composition is provided,the composition comprising a plurality of conjugates, wherein at leastabout 80% of all conjugates in the composition are each comprised of aFactor IX moiety covalently attached to one, two, three or fourwater-soluble polymers, and further wherein for each water-solublepolymer in the conjugate, the Factor IX moiety is attached to thewater-soluble polymer either directly or through a spacer moietycomprised of one or more atoms.

With respect to the conjugates in the composition, the composition willtypically satisfy one or more of the following characteristics: at leastabout 85% of the conjugates in the composition will have from one tofive polymers attached to the Factor IX moiety; at least about 85% ofthe conjugates in the composition will have from one to four polymersattached to the Factor IX moiety; at least about 85% of the conjugatesin the composition will have from one to three polymers attached to theFactor IX moiety; at least about 85% of the conjugates in thecomposition will have from one to two polymers attached to the Factor IXmoiety; at least about 85% of the conjugates in the composition willhave one polymer attached to the Factor IX moiety (i.e., bemonoPEGylated); at least about 95% of the conjugates in the compositionwill have from one to five polymers attached to the Factor IX moiety; atleast about 95% of the conjugates in the composition will have from oneto four polymers attached to the Factor IX moiety; at least about 95% ofthe conjugates in the composition will have from one to three polymersattached to the Factor IX moiety; at least about 95% of the conjugatesin the composition will have from one to two polymers attached to theFactor IX moiety; at least about 95% of the conjugates in thecomposition will have one polymer attached to the Factor IX moiety(i.e., be monoPEGylated); at least about 99% of the conjugates in thecomposition will have from one to five polymers attached to the FactorIX moiety; at least about 99% of the conjugates in the composition willhave from one to four polymers attached to the Factor IX moiety; atleast about 99% of the conjugates in the composition will have from oneto three polymers attached to the Factor IX moiety; at least about 99%of the conjugates in the composition will have from one to two polymersattached to the Factor IX moiety; and at least about 99% of theconjugates in the composition will have one polymer attached to theFactor IX moiety (i.e., be monoPEGylated).

In one or more embodiments, it is preferred that theconjugate-containing composition is free or substantially free ofalbumin. It is also preferred that the composition is free orsubstantially free of proteins that do not have Factor IX activity.Thus, it is preferred that the composition is 85%, more preferably 95%,and most preferably 99% free of albumin. Additionally, it is preferredthat the composition is 85%, more preferably 95%, and most preferably99% free of any protein that does not have Factor IX activity. To theextent that albumin is present in the composition, exemplarycompositions of the invention are substantially free of conjugatescomprising a poly(ethylene glycol) polymer linking a residue of a FactorIX moiety to albumin.

Control of the desired number of polymers for any given moiety can beachieved by selecting the proper polymeric reagent, the ratio ofpolymeric reagent to the Factor IX moiety, temperature, pH conditions,and other aspects of the conjugation reaction. In addition, reduction orelimination of the undesired conjugates (e.g., those conjugates havingfour or more attached polymers) can be achieved through purificationmeans.

For example, the polymer-Factor IX moiety conjugates can be purified toobtain/isolate different conjugated species. Specifically, the productmixture can be purified to obtain an average of anywhere from one, two,three, four, five or more PEGs per Factor IX moiety, typically one, twoor three PEGs per Factor IX moiety. The strategy for purification of thefinal conjugate reaction mixture will depend upon a number of factors,including, for example, the molecular weight of the polymeric reagentemployed, the particular Factor IX moiety, the desired dosing regimen,and the residual activity and in vivo properties of the individualconjugate(s).

If desired, conjugates having different molecular weights can beisolated using gel filtration chromatography and/or ion exchangechromatography. That is to say, gel filtration chromatography is used tofractionate differently numbered polymer-to-Factor IX moiety ratios(e.g., 1-mer, 2-mer, 3-mer, and so forth, wherein “1-mer” indicates 1polymer attached to a Factor IX moiety, “2-mer” indicates two polymersattached to Factor IX moiety, and so on) on the basis of their differingmolecular weights (where the difference corresponds essentially to theaverage molecular weight of the water-soluble polymer portion). Forexample, in an exemplary reaction where a 55,000 Dalton protein israndomly conjugated to a polymeric reagent having a molecular weight ofabout 20,000 Daltons, the resulting reaction mixture may containunmodified protein (having a molecular weight of about 55,000 Daltons),monoPEGylated protein (or “1-mer”) (having a molecular weight of about75,000 Daltons), diPEGylated protein (or 2-mer” (having a molecularweight of about 95,000 Daltons), and so forth.

While this approach can be used to separate PEG and other polymer-FactorIX moiety conjugates having different molecular weights, this approachis generally ineffective for separating positional isomers havingdifferent polymer attachment sites within the Factor IX moiety. Forexample, gel filtration chromatography can be used to separate from eachother mixtures of 1-mers, 2-mers, 3-mers, and so forth, although each ofthe recovered PEG-mer compositions may contain PEGs attached todifferent reactive amino groups (e.g., lysine residues) within Factor IXmoiety.

Gel filtration columns suitable for carrying out this type of separationinclude Superdex™ and Sephadex™ columns available from AmershamBiosciences (Piscataway, N.J.). Selection of a particular column willdepend upon the desired fractionation range desired. Elution isgenerally carried out using a suitable buffer, such as phosphate,acetate, or the like. The collected fractions may be analyzed by anumber of different methods, for example, (i) absorbance at 280 nm forprotein content, (ii) dye-based protein analysis using bovine serumalbumin as a standard, (iii) iodine testing for PEG content (Sims et al.(1980) Anal. Biochem, 107:60-63), (iv) sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS PAGE), followed by staining withbarium iodide, and higher performance liquid chromatography.

Separation of positional isomers can be carried out by reverse phasechromatography using reverse phase-high performance liquidchromatography (RP-HPLC) methods using for example a C18 column or C3column (Amersham Biosciences or Vydac) or by ion exchange chromatographyusing an ion exchange column, e.g., a Sepharose™ ion exchange columnavailable from Amersham Biosciences. Either approach can be used toseparate polymer-active agent isomers having the same molecular weight(positional isomers).

The compositions are preferably substantially free of proteins that donot have Factor IX activity. In addition, the compositions preferablyare substantially free of all other noncovalently attached water-solublepolymers. In some circumstances, however, the composition can contain amixture of polymer-Factor IX moiety conjugates and unconjugated FactorIX.

Optionally, the composition of the invention further comprises apharmaceutically acceptable excipient. If desired, the pharmaceuticallyacceptable excipient can be added to a conjugate to form a composition.

Exemplary excipients include, without limitation, those selected fromthe group consisting of carbohydrates, inorganic salts, antimicrobialagents, antioxidants, surfactants, buffers, acids, bases, andcombinations thereof.

A carbohydrate such as a sugar, a derivatized sugar such as an alditol,aldonic acid, an esterified sugar, and/or a sugar polymer may be presentas an excipient. Specific carbohydrate excipients include, for example:monosaccharides, such as fructose, maltose, galactose, glucose,D-mannose, sorbose, and the like; disaccharides, such as lactose,sucrose, trehalose, cellobiose, and the like; polysaccharides, such asraffinose, melezitose, maltodextrins, dextrans, starches, and the like;and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol,sorbitol (glucitol), pyranosyl sorbitol, myoinositol, and the like.

The excipient can also include an inorganic salt or buffer such ascitric acid, sodium chloride, potassium chloride, sodium sulfate,potassium nitrate, sodium phosphate monobasic, sodium phosphate dibasic,and combinations thereof.

The composition can also include an antimicrobial agent for preventingor deterring microbial growth. Nonlimiting examples of antimicrobialagents suitable for the present invention include benzalkonium chloride,benzethonium chloride, benzyl alcohol, cetylpyridinium chloride,chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate,thimersol, and combinations thereof.

An antioxidant can be present in the composition as well. Antioxidantsare used to prevent oxidation, thereby preventing the deterioration ofthe conjugate or other components of the preparation. Suitableantioxidants for use in the present invention include, for example,ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene,hypophosphorous acid, monothioglycerol, propyl gallate, sodiumbisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, andcombinations thereof.

A surfactant can be present as an excipient. Exemplary surfactantsinclude: polysorbates, such as “Tween 20” and “Tween 80,” and pluronicssuch as F68 and F88 (both of which are available from BASF, Mount Olive,N.J.); sorbitan esters; lipids, such as phospholipids such as lecithinand other phosphatidylcholines, phosphatidylethanolamines (althoughpreferably not in liposomal form), fatty acids and fatty esters;steroids, such as cholesterol; and chelating agents, such as EDTA, zincand other such suitable cations.

Acids or bases can be present as an excipient in the composition.Nonlimiting examples of acids that can be used include those acidsselected from the group consisting of hydrochloric acid, acetic acid,phosphoric acid, citric acid, malic acid, lactic acid, formic acid,trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid,sulfuric acid, fumaric acid, and combinations thereof. Examples ofsuitable bases include, without limitation, bases selected from thegroup consisting of sodium hydroxide, sodium acetate, ammoniumhydroxide, potassium hydroxide, ammonium acetate, potassium acetate,sodium phosphate, potassium phosphate, sodium citrate, sodium formate,sodium sulfate, potassium sulfate, potassium fumerate, and combinationsthereof.

The amount of the conjugate (i.e., the conjugate formed between theactive agent and the polymeric reagent) in the composition will varydepending on a number of factors, but will optimally be atherapeutically effective amount when the composition is stored in aunit dose container (e.g., a vial). In addition, the pharmaceuticalpreparation can be housed in a syringe. A therapeutically effectiveamount can be determined experimentally by repeated administration ofincreasing amounts of the conjugate in order to determine which amountproduces a clinically desired endpoint.

The amount of any individual excipient in the composition will varydepending on the activity of the excipient and particular needs of thecomposition. Typically, the optimal amount of any individual excipientis determined through routine experimentation, i.e., by preparingcompositions containing varying amounts of the excipient (ranging fromlow to high), examining the stability and other parameters, and thendetermining the range at which optimal performance is attained with nosignificant adverse effects.

Generally, however, the excipient will be present in the composition inan amount of about 1% to about 99% by weight, preferably from about 5%to about 98% by weight, more preferably from about 15 to about 95% byweight of the excipient, with concentrations less than 30% by weightmost preferred.

These foregoing pharmaceutical excipients along with other excipientsare described in “Remington: The Science & Practice of Pharmacy”,19^(th) ed., Williams & Williams, (1995), the “Physician's DeskReference”, 52^(nd) ed., Medical Economics, Montvale, N.J. (1998), andKibbe, A.H., Handbook of Pharmaceutical Excipients, 3^(rd) Edition,American Pharmaceutical Association, Washington, D.C., 2000.

The compositions encompass all types of formulations and in particularthose that are suited for injection, e.g., powders or lyophilates thatcan be reconstituted as well as liquids.

Examples of suitable diluents for reconstituting solid compositionsprior to injection include bacteriostatic water for injection, dextrose5% in water, phosphate-buffered saline, Ringer's solution, saline,sterile water, deionized water, and combinations thereof. With respectto liquid pharmaceutical compositions, solutions and suspensions areenvisioned.

The compositions of the present invention are typically, although notnecessarily, administered via injection and are therefore generallyliquid solutions or suspensions immediately prior to administration. Thepharmaceutical preparation can also take other forms such as syrups,creams, ointments, tablets, powders, and the like. Other modes ofadministration are also included, such as pulmonary, rectal,transdermal, transmucosal, oral, intrathecal, subcutaneous,intra-arterial, and so forth.

The invention also provides a method for delivering a conjugate asprovided herein to a patient suffering from a condition that isresponsive to treatment with conjugate. The method comprises delivering,generally via injection, a therapeutically effective amount of theconjugate (preferably provided as part of a pharmaceutical composition).The conjugates (typically as part of a pharmaceutical composition) canbe delivered by, for example, intravenous injection, intramuscularinjection, subcutaneous injection, and so forth. Suitable formulationtypes for parenteral administration include ready-for-injectionsolutions, dry powders for combination with a solvent prior to use,suspensions ready for injection, dry insoluble compositions forcombination with a vehicle prior to use, and emulsions and liquidconcentrates for dilution prior to administration, among others.

The method of delivering may be used to treat a patient having acondition that can be remedied or prevented by administration of theconjugate. Those of ordinary skill in the art appreciate whichconditions a specific conjugate can effectively treat. For example, theconjugates can be used to treat individuals suffering from hemophilia B,either as a replacement therapy or on a prophylaxis basis.Administration of the conjugate for prophylaxis includes situationswhere a patient suffering from hemophilia B is about to undergo surgeryand the conjugate is administered between one to four hours prior tosurgery. In addition, the conjugates are suited for use as aprophylactic against uncontrolled bleeding, optionally in patients notsuffering from hemophilia. Thus, for example, the conjugate can beadministered to a patient at risk for uncontrolled bleeding prior tosurgery.

The actual dose to be administered will vary depend upon the age,weight, and general condition of the subject as well as the severity ofthe condition being treated, the judgment of the health careprofessional, and conjugate being administered. Therapeuticallyeffective amounts are known to those skilled in the art and/or aredescribed in the pertinent reference texts and literature. Generally, ona weight basis, a therapeutically effective amount will range from about0.001 mg to 100 mg, preferably in doses from 0.01 mg/day to 75 mg/day,and more preferably in doses from 0.10 mg/day to 50 mg/day. On anactivity basis, corresponding doses based on international units ofactivity can be calculated by one of ordinary skill in the art.

The unit dosage of any given conjugate (again, preferably provided aspart of a pharmaceutical composition) can be administered in a varietyof dosing schedules depending on the judgment of the clinician, needs ofthe patient, and so forth. The specific dosing schedule will be known bythose of ordinary skill in the art or can be determined experimentallyusing routine methods. Exemplary dosing schedules include, withoutlimitation, administration five times a day, four times a day, threetimes a day, twice daily, once daily, three times weekly, twice weekly,once weekly, twice monthly, once monthly, and any combination thereof.Once the clinical endpoint has been achieved, dosing of the compositionis halted.

It is to be understood that while the invention has been described inconjunction with the preferred specific embodiments thereof, that theforegoing description as well as the examples that follow are intendedto illustrate and not limit the scope of the invention. Other aspects,advantages and modifications within the scope of the invention will beapparent to those skilled in the art to which the invention pertains.

All articles, books, patents and other publications referenced hereinare hereby incorporated by reference in their entireties.

EXPERIMENTAL

The practice of the invention will employ, unless otherwise indicated,conventional techniques of organic synthesis and the like, which arewithin the skill of the art. Such techniques are fully explained in theliterature. Reagents and materials are commercially available unlessspecifically stated to the contrary. See, for example, J. March,Advanced Organic Chemistry Reactions Mechanisms and Structure, 4th Ed.(New York: Wiley-Interscience, 1992), supra.

In the following examples, efforts have been made to ensure accuracywith respect to numbers used (e.g., amounts, temperatures, etc.) butsome experimental error and deviation should be accounted for. Unlessindicated otherwise, temperature is in degrees C. and pressure is at ornear atmospheric pressure at sea level.

Although other abbreviations known by one having ordinary skill in theart will be referenced, other reagents and materials will be used, andother methods known by one having ordinary skill in the art will beused, the following list and methods description is provided for thesake of convenience.

NaCNB H₃ sodium cyanoborohydride, 95% (Aldrich)

HCl hydrochloric acid, glacial (Fisher)

K or kDa kilodaltons

Acetonitrile (Fisher Optima)

TFA Trifluoroacetic acid, HPLC grade (JT Baker)

PBS Phosphate buffered saline (Sigma)

SEC Size exclusion chromatography

HPLC high performance liquid chromatography

SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis

HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] biotechnologyperformance certified, 99.5+% (Sigma)

Ethyl alcohol,USP, Absolute-200 Proof (AAPER)

NuPAGE® MES [2-(N-morpholino)ethane sulfonic acid] SDS running buffer(Invitrogen Corporation, Carlsbad Calif.)

NuPAGE® 4×LDS (lithium docecyl sulfate) sample buffer (InvitrogenCorporation, Carlsbad Calif.)

SigmaMarker, low range (M.W. 6,500-66,000) (Sigma)

SigmaMarker, high range (M.W. 36,000-205,000) (Sigma)

NuPAGE® Novex Bis-Tris[Bis(2-hydroxyethyl)imino-tris(hydroxymethyl)methane-HCl] gel(Invitrogen Corporation, Carlsbad Calif.)

SEC-HPLC Analysis

Size exclusion chromatography (SEC) was performed on an Agilent 1100HPLC system (Agilent). For those samples analyzed using SEC-HPLC, eachsample was analyzed using a SHODEX protein KW-804 column (Showa Denko KK, Tokyo Japan), at pH 7.2. The flow rate for the column was set at 0.5mL/minute. Eluted protein and PEG-protein conjugates were detected usingan UV-based approach having a wavelength set at 280 nm.

SDS-PAGE Analysis

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) wasperformed using an XCELL SURELOCK Mini-Cell electrophoresis system(Invitrogen Corporation, Carlsbad Calif.). For those samples analyzedusing SDS-PAGE, each sample was mixed with 4×LDS Sample Buffer(Invitrogen Corporation, Carlsbad Calif.). The prepared samples werethen loaded onto a NuPAGE Novex 4-12% Bis-Tris gel and run forapproximately thirty minutes at 200 V using NuPAGE® MES running buffer(Invitrogen Corporation, Carlsbad Calif.).

RP-HPLC Analysis

Reverse phase-high performance liquid chromatography was performed usinga C3 reverse column (Hamilton, Zorbax). A 30-80% gradient ofacetonitrile was used along with an elevated temperature over thirtyminutes at 0.5 mL/minute.

Recombinant Factor IX corresponding to the amino acid sequence of SEQ.ID. NO. 1. was used in Examples 1-16. Factor IX was obtained in a buffercontaining both L-histidine and glycine. Because the amine groupsassociated with L-histidine and glycine in the buffer would compete foramine groups associated with Factor IX, it was necessary to exchange theamine-containing buffer for an amine-free buffer to improve the FactorIX conjugation yield when amine-directed polymeric reagents were used toeffect conjugation.

Briefly, the amine-containing buffer was exchanged for an amine-freebuffer by one of two approaches, depending on the volume of buffer to beexchanged. For relatively small volumes of buffer, a 500 μL Zeba Desaltcentrifuge column (Pierce Biotechnology, Rockford Ill.) was usedaccording to the protocol provided by the manufacturer. For relativelylarge volumes of buffer, a 2 mL CENTRICON® centrifugal filter device(Millipore Corporation, Billerica Mass.) with a 10,000 or 30,000 Daltonmolecular weight cutoff was used according to the protocol provided bythe manufacturer. All samples used in the Examples without ethanol werechanged to a 1×PBS buffer having a pH of 7.5, while all samples used inthe Examples with ethanol were exchanged to a 1×PBS buffer having a pHof 7.5 with ethanol added to form a 10% ethanol-containing Factor IXreaction mixture.

The amine-free buffer containing recombinant Factor IX corresponding tothe amino acid sequence of SEQ. ID. NO. 1. (the “Factor IX stocksolution”) was used in Examples 1-16. The Factor IX stock solutioncontained about 0.2 mg/mL to 0.55 mg/mL of Factor IX.

Example 1 PEGylation of Factor IX with mPEG-SMB, 30 kDa (1:1 Polymer toFactor IX Ratio; without Ethanol)

mPEG-SMB, 30 kDa, stored at −20° C. under argon, was warmed to ambienttemperature. The warmed mPEG-SMB (4.1 mg) was dissolved in 1 mL of 2 mMHCl to form an mPEG-SMB solution. The mPEG-SMB solution was added to analiquot of the Factor IX stock solution containing 0.07 mg of Factor IXuntil a one:one molar ratio of mPEG-SMB relative to Factor IX wasreached. After the addition of the mPEG-SMB, the pH of the reaction wastested to ensure a pH of 7.2. to 7.5, and mixed well. To allow forcoupling of the mPEG-SMB to Factor IX via an amide linkage, the reactionsolution was stirred for three hours at room temperature, after whichSDS PAGE was run on the sample, which confirmed the presence ofmonoconjugated material (“1-mer”). See the lane labeled as “1:1 30K SMB”in the gel provided as FIG. 1. Thereafter, coupling was allowed tocontinue by stirring the reaction solution for fifteen hours at 4° C.,thereby resulting in a conjugate solution.

RP-HPLC (C₃) and a second SDS PAGE were used for the characterization ofthe resulting conjugate solution. Based on the second SDS PAGE result,conjugation was shown. See the lane labeled as “1:1 30K SMB” in the gelprovided as FIG. 2. RP-HPLC(C₃) was used to separate the components ofthe resulting conjugate solution and the resulting chromatogramindicated a yield of 0.54% (representing 100% monoPEGyled or “1-mer”species). See the chromatagram provided as FIG. 5.

It is expected that longer reactions times, increase temperatures and/ormultiple additions of the polymeric reagent could increase yields. Usingthis same approach, other conjugates can be prepared using mPEG-SMBhaving other weight-average molecular weights.

Example 2 PEGylation of Factor IX with mPEG-SMB, 30 kDa (10:1 Polymer toFactor IX Ratio; without Ethanol)

mPEG-SMB, 30 kDa, stored at −20° C. under argon, was warmed to ambienttemperature. The warmed mPEG-SMB (4.1 mg) was dissolved in 1 mL of 2 mMto form an mPEG-SMB solution. The mPEG-SMB solution was added to analiquot of the Factor IX stock solution containing 0.07 mg of Factor IXuntil a ten molar excess of mPEG-SMB relative to Factor IX was reached.After the addition of the mPEG-SMB, the pH of the reaction mixture wastested to ensure a pH of 7.2 to 7.5, and mixed well. To allow forcoupling of the mPEG-SMB to Factor IX via an amide linkage, the reactionsolution was stirred for three hours at room temperature, after whichSDS PAGE was run on the sample, which confirmed the presence ofmonoconjugated material (“1-mer”). See the lane labeled as “10:1 30KSMB” in the gel provided as FIG. 1. Thereafter, coupling was allowed tocontinue by stirring the reaction solution for fifteen hours at 4° C.,thereby resulting in a conjugate solution.

RP-HPLC (C₃) and a second SDS PAGE were used for the characterization ofthe resulting conjugate solution. Based on the second SDS PAGE results,conjugation was shown. See the lane labeled as “10:1 30K SMB” in the gelprovided as FIG. 2. RP-HPLC (C₃) was used to separate the components ofthe resulting conjugate solution and the resulting chromatogramindicated a yield of 6.4% (representing 100% monoPEGyled or “1-mer”species). See the chromatagram provided as FIG. 6.

It is expected that longer reactions times, increased temperaturesand/or multiple additions of the polymeric reagent could increaseyields. Thus, when this experiment was repeated for an extended time atroom temperature prior to continuing the reaction overnight at 4° C., anincrease conjugate yield resulted as evidenced by a darker band as seenin an SDS PAGE gel. See the lane labeled as “10:1 30K SMB” in FIG. 4.Using the same approaches described here, other conjugates can beprepared using mPEG-SMB having other weight-average molecular weights.

Example 3 PEGylation of Factor IX with BranchedmPEG2-N-Hydroxysuccinimide, 40 kDa (1:1 Polymer to Factor IX Ratio;without Ethanol)

Branched mPEG2-N-hydroxysuccinimide, 40 kDa, stored at −20° C. underargon, was warmed to ambient temperature. The warmed branchedmPEG2-N-hydroxysuccinimide (2.0 mg) was dissolved in 1 mL of 2 mM HCl toform a branched mPEG2-N-hydroxysuccinimide solution. The branchedmPEG2-N-hydroxysuccinimide solution was added to an aliquot of theFactor IX stock solution containing 0.07 mg of Factor IX until a one:onemolar ratio of branched mPEG2-N-hydroxysuccinimide relative to Factor IXwas reached. After the addition of branched mPEG2-N-hydroxysuccinimide,the pH of the reaction mixture was tested to ensure a pH of 7.2 to 7.5,and mixed well. To allow for coupling of the branchedmPEG2-N-hydroxysuccinimide to Factor IX via an amide linkage, thereaction solution was stirred for three hours at room temperature, afterwhich SDS PAGE was run on the sample, which showed no detectableconjugation. See the lane labeled as “1:1 40K NHS” in the gel providedas FIG. 1. Thereafter, addition time for conjugation was provided bystirring the reaction solution for fifteen hours at 4° C., therebyresulting in a conjugate solution.

RP-HPLC (C₃) and a second SDS PAGE were used for the characterization ofthe resulting conjugate solution. Based on the second SDS PAGE results,conjugation was shown. See the lane labeled as “1:1 40K NHS” in the gelprovided as FIG. 2. RP-HPLC (C₃) was used to separate the components ofthe resulting conjugate solution and the resulting chromatogramindicated a yield of 0.1% (representing 100% monoPEGyled or “1-mer”species). See the chromatagram provided as FIG. 7.

It is expected that longer reactions times, increased temperaturesand/or multiple additions of the polymeric reagent could increaseyields. Using this same approach, other conjugates can be prepared usingbranched mPEG2-N-hydroxysuccinimide having other weight-averagemolecular weights.

Example 4 PEGylation of Factor IX with BranchedmPEG2-N-Hydroxysuccinimide, 40kDa (10:1 Polymer to Factor IX Ratio;without Ethanol)

Branched mPEG2-N-hydroxysuccinimide, 40 kDa, stored at −20° C. underargon, was warmed to ambient temperature. The warmed branchedmPEG2-N-hydroxysuccinimide (2.0 mg) was dissolved in 1 mL of 2 mM HCl toform a branched mPEG2-N-hydroxysuccinimide solution. The branchedmPEG2-N-hydroxysuccinimide solution was added to an aliquot of theFactor IX stock solution containing 0.07 mg of Factor IX until a tenmolar excess of branched mPEG2-N-hydroxysuccinimide relative to FactorIX was reached. After the addition of branchedmPEG2-N-hydroxysuccinimide, the pH of the reaction mixture was tested toensure a pH of 7.2 to 7.5, and mixed well. To allow for coupling of thebranched mPEG2-N-hydroxysuccinimide to Factor IX via an amide linkage,the reaction solution was stirred for three hours at room temperature,after which SDS PAGE was run on the sample, which showed no detectableconjugation. See the lane labeled as 10:1 40 k NHS” in the gel providedas FIG. 1. Thereafter, coupling was allowed to continue by stirring thereaction solution for fifteen hours at 4° C., thereby resulting in aconjugate solution.

RP-HPLC (C₃) and a second SDS PAGE were used for the characterization ofthe resulting conjugate solution. Based on the second SDS PAGE results,conjugation was still not detectable. See the lane labeled as “10:1 40KNHS” in the gel provided as FIG. 2. RP-HPLC (C₃) was used to separatethe components of the resulting conjugate solution and the resultingchromatogram indicated no detectable conjugate yield. See thechromatagram provided as FIG. 8.

It is expected that longer reactions times, increased temperaturesand/or multiple additions of the polymeric reagent could increaseyields. Using this same approach, other conjugates can be prepared usingbranched mPEG2-N-hydroxysuccinimide having other weight-averagemolecular weights.

Example 5 PEGylation of Factor IX with mPEG-SMB, 30 kDa (10:1 Polymer toFactor IX Ratio; with Ethanol)

As ethanol is believed to increase the structural flexibility of certainproteins, ethanol was introduced into the buffer and reaction system.mPEG-SMB, 30 kDa, stored at −20° C. under argon, was warmed to ambienttemperature. The warmed mPEG-SMB (10.0 mg) was dissolved in 0.5 mL of 2mM HCl with ethanol added to form a 10% ethanol-containing mPEG-SMBsolution. The 10% ethanol-containing mPEG-SMB solution was added to the10% ethanol-containing Factor IX reaction mixture until a ten molarexcess of mPEG-SMB relative to Factor IX was reached. After the additionof the mPEG-SMB, the pH of the reaction mixture was tested to ensure apH of 7.2 to 7.5, and mixed well. To allow for coupling of the mPEG-SMBto Factor IX via an amide linkage, the reaction solution was stirred forthree hours at room temperature. Coupling was allowed to continue bystirring the reaction solution overnight at 4° C., thereby resulting ina conjugate solution.

SDS PAGE was used for the characterization of the resulting conjugatesolution. Based on the SDS PAGE results, conjugation was not detected.See the lane labeled as “10:1 30K SMB+EtOH” in the gel provided as FIG.3. It is now believed that the introduction of ethanol does not increasethe structural flexibility of Factor IX to allow for increasedconjugation of mPEG-SMB, 30 kDa.

It is expected that longer reactions times, increased temperaturesand/or multiple additions of the polymeric reagent could increaseyields. Using this same approach, other conjugates can be prepared usingmPEG-SMB having other weight-average molecular weights.

Example 6 PEGylation of Factor IX with mPEG-SMB, 30kDa (20:1 Polymer toFactor IX Ratio; with Ethanol)

As ethanol is believed to increase the structural flexibility of certainproteins, ethanol was introduced into the buffer and reaction system.mPEG-SMB, 30 kDa, stored at −20° C. under argon, was warmed to ambienttemperature. The warmed mPEG-SMB (10.0 mg) was dissolved in 0.5 mL of 2mM HCl with ethanol added to form a 10% ethanol-containing mPEG-SMBsolution. The 10% ethanol-containing mPEG-SMB solution was added to the10% ethanol-containing Factor IX reaction mixture until a twenty molarexcess of mPEG-SMB relative to Factor IX was reached. After the additionof the mPEG-SMB, the pH of the reaction mixture was tested to ensure apH of 7.2 to 7.5, and mixed well. To allow for coupling of the mPEG -SMBto Factor IX via an amide linkage, the reaction solution was stirred forthree hours at room temperature. Coupling was allowed to continue bystirring the reaction solution overnight at 4° C., thereby resulting ina conjugate solution.

SDS PAGE was used for the characterization of the resulting conjugatesolution. Based on the SDS PAGE results, conjugation was not detected.See the lane labeled as “20:1 30K SMB+EtOH” in the gel provided as FIG.3. It is now believed that the introduction of ethanol does not increasethe structural flexibility of Factor IX to allow for increasedconjugation of mPEG-SMB, 30 kDa.

It is expected that longer reactions times, increased temperaturesand/or multiple additions of the polymeric reagent could increaseyields. Using this same approach, other conjugates can be prepared usingmPEG-SMB having other weight-average molecular weights.

Example 7 PEGylation of Factor IX with BranchedmPEG2-N-Hydroxysuccinimide, 40 kDa (10:1 Polymer to Factor IX Ratio;with Ethanol)

As ethanol is believed to increase the structural flexibility of certainproteins, ethanol was introduced into the buffer and reaction system.Branched mPEG2-N-hydroxysuccinimide, 40 kDa, stored at −20° C. underargon, was warmed to ambient temperature. The warmed branchedmPEG2-N-hydroxysuccinimide (2.0 mg) was dissolved in 1.0 mL of 2 mM HClwith ethanol added to form a 10% ethanol-containing branchedmPEG2-N-hydroxysuccinimide solution. The 10% ethanol-containing branchedmPEG2-N-hydroxysuccinimide solution was added to the 10%ethanol-containing Factor IX reaction mixture until a ten molar excessof branched mPEG2-N-hydroxysuccinimide relative to Factor IX wasreached. After the addition of branched mPEG2-N-hydroxysuccinimide, thepH of the reaction mixture was tested to ensure a pH of 7.2 to 7.5, andmixed well. To allow for coupling of the branchedmPEG2-N-hydroxysuccinimide to Factor IX via an amide linkage, thereaction solution was stirred for three hours at room temperature.Coupling was allowed to continue by stirring the reaction solutionovernight at 4° C., thereby resulting in a conjugate solution.

SDS PAGE was used for the characterization of the resulting conjugatesolution. Based on the SDS PAGE results, conjugation was not detected(results not shown). It is now believed that the introduction of ethanoldoes not increase the structural flexibility of Factor IX to allow forincreased conjugation of branched mPEG2-N-hydroxysuccinimide, 40 kDa.

It is expected that longer reactions times, increased temperaturesand/or multiple additions of the polymeric reagent could increaseyields. Using this same approach, other conjugates can be prepared usingbranched mPEG2-N-hydroxysuccinimide having other weight-averagemolecular weights.

Example 8 PEGylation of Factor IX with BranchedmPEG2-N-Hydroxysuccinimide, 40 kDa (20:1 Polymer to Factor IX Ratio;with ethanol)

As ethanol is believed to increase the structural flexibility of certainproteins, ethanol was introduced into the buffer and reaction system.Branched mPEG2-N-hydroxysuccinimide, 40 kDa, stored at −20° C. underargon, was warmed to ambient temperature. The warmed branchedmPEG2-N-hydroxysuccinimide (2.0 mg) was dissolved in 1.0 mL of 2 mM HClwith ethanol added to form a 10% ethanol-containing branchedmPEG2-N-hydroxysuccinimide solution. The 10% ethanol-containing branchedmPEG2-N-hydroxysuccinimide solution was added to the 10%ethanol-containing Factor IX reaction mixture until a twenty molarexcess of branched mPEG2-N-hydroxysuccinimide relative to Factor IX wasreached. After the addition of branched mPEG2-N-hydroxysuccinimide, thepH of the reaction mixture was tested to ensure a pH of 7.2 to 7.5, andmixed well. To allow for coupling of the branchedmPEG2-N-hydroxysuccinimide to Factor IX via an amide linkage, thereaction solution was stirred for three hours at room temperature.Coupling was allowed to continue by stirring the reaction solutionovernight at 4° C., thereby resulting in a conjugate solution.

SDS PAGE was used for the characterization of the resulting conjugatesolution. Based on the SDS PAGE results, conjugation was not detected(results not shown). It is now believed that the introduction of ethanoldoes not increase the structural flexibility of Factor IX to allow forincreased conjugation of branched mPEG2-N-hydroxysuccinimide, 40 kDa.

It is expected that longer reactions times, increased temperaturesand/or multiple additions of the polymeric reagent could increaseyields. Using this same approach, other conjugates can be prepared usingbranched mPEG2-N-hydroxysuccinimide having other weight-averagemolecular weights.

Example 9 PEGylation of Factor IX with mPEG-SMB, 30 kDa (20:1 Polymer toFactor IX Ratio; without Ethanol)

mPEG-SMB, 30 kDa, stored at −20° C. under argon, was warmed to ambienttemperature. The warmed mPEG-SMB (8.6 mg) was dissolved in 1.0 mL of 2mM HCl to form an mPEG-SMB solution. The mPEG-SMB solution was added toan aliquot of the Factor IX stock solution containing 0.07 mg of FactorIX until a twenty molar excess of mPEG-SMB relative to Factor IX wasreached. After the addition of the mPEG-SMB, the pH of the reactionmixture was tested to ensure a pH of 7.2 to 7.5. To allow for couplingof the mPEG-SMB to Factor IX via an amide linkage, the reaction solutionwas stirred for two hours at room temperature. Coupling was allowed tocontinue by stirring the reaction solution overnight at 4° C., therebyresulting in a conjugate solution. Thereafter, coupling was allowed tocontinue by stirring overnight at 4° C., thereby resulting in aconjugate solution.

SDS PAGE was used for the characterization. Based on the second SDS PAGEresults, conjugation was shown. See the lane labeled as “20:1 30K SMB”in the gel provided as FIG. 4.

It is expected that longer reactions times, increased temperaturesand/or multiple additions of the polymeric reagent could increaseyields. Using this same approach, other conjugates can be prepared usingbranched mPEG-SMB having other weight-average molecular weights.

Example 10 PEGylation of Factor IX with mPEG-SPA, 20 kDa (20:1 Polymerto Factor IX Ratio; with Ethanol)

As ethanol is believed to increase the structural flexibility of certainproteins, ethanol was introduced into the buffer and reaction system.mPEG-SPA, 20 kDa, stored at −20° C. under argon, was warmed to ambienttemperature. The warmed mPEG-SPA (10.0 mg) was dissolved in 0.5 mL of 2mM HCl with ethanol added to form a 10% ethanol-containing mPEG-SPAsolution. The 10% ethanol-containing mPEG-SPA solution was added to the10% ethanol-containing Factor IX reaction mixture until a twenty molarexcess of mPEG-SPA relative to Factor IX was reached. After the additionof the mPEG-SPA, the pH of the reaction mixture was tested to ensure apH of 7.2 to 7.5, and mixed well. To allow for coupling of the mPEG-SPAto Factor IX via an amide linkage, the reaction solution was stirred fortwo hours at room temperature. Coupling was allowed to continue bystirring the reaction solution.

Based on SDS PAGE results, conjugation was not detected. See the lanelabeled as “20:1 20K SPA+EtOH” in the gel provided as FIG. 3. It is nowbelieved that the introduction of ethanol does not increase thestructural flexibility of Factor IX to allow for increased conjugationof mPEG-SPA, 20 kDa.

It is expected that longer reactions times, increased temperaturesand/or multiple additions of the polymeric reagent could increaseyields. Using this same approach, other conjugates can be prepared usingmPEG-SPA having other weight-average molecular weights.

Example 11 PEGylation of Factor IX with mPEG-SPA, 20 kDa (40:1 Polymerto Factor IX Ratio; with Ethanol)

As ethanol is believed to increase the structural flexibility of certainproteins, ethanol was introduced into the buffer and reaction system.mPEG-SPA, 20 kDa, stored at −20° C. under argon, was warmed to ambienttemperature. The warmed mPEG-SPA (10.0 mg) was dissolved in 0.5 mL of 2mM HCl with ethanol added to form a 10% ethanol-containing mPEG-SPAsolution. The 10% ethanol-containing mPEG-SPA solution was added to the10% ethanol-containing Factor IX reaction mixture until a forty molarexcess of mPEG-SPA relative to Factor IX was reached. After the additionof the mPEG-SPA, the pH of the reaction mixture was tested to ensure apH of 7.2 to 7.5, and mixed well. To allow for coupling of the mPEG-SPAto Factor IX via an amide linkage, the reaction solution was stirred fortwo hours at room temperature. Coupling was allowed to continue bystirring the reaction solution.

Based on SDS PAGE results, conjugation was not detected. See the lanelabeled as “40:1 20K SPA+EtOH” in the gel provided as FIG. 3. It is nowbelieved that the introduction of ethanol does not increase thestructural flexibility of Factor IX to allow for increased conjugationof mPEG-SPA, 20 kDa.

It is expected that longer reactions times, increased temperaturesand/or multiple additions of the polymeric reagent could increaseyields. Using this same approach, other conjugates can be prepared usingmPEG-SPA having other weight-average molecular weights.

Example 12 PEGylation of Factor IX with Branched mPEG-Butyraldehyde, 20kDa (10:1 Polymer to Factor IX Ratio; without Ethanol)

Branched mPEG2-Butyraldehyde, 20 kDa, stored at −20° C. under argon, waswarmed to ambient temperature. The warmed branched mPEG2-butyraldehyde(10.9 mg) was dissolved in 1 mL of 2 mM HCl to form a branchedmPEG2-butyraldehyde solution. The branched mPEG2-butyraldehyde solutionwas added to an aliquot of the Factor IX stock solution containing 0.07mg of Factor IX until a ten molar excess of branched mPEG2-butyraldehydeto Factor IX was reached. After thirty minutes of mixing, a reducingagent, NaCNBH₃ (dissolved in 1×PBS), was added at excess relative to thebranched mPEG2-butyraldehyde (with the pH tested and adjusted asnecessary to ensure reduction to the secondary amine). The solution wasthen stirred overnight at 4° C. to ensure coupling via an amine linkage.

RP-HPLC (C₃) and a SDS PAGE were used for the characterization of theresulting conjugate solution. Based on the SDS PAGE results, conjugationwas not detected. See the lane labeled as “10:1 20K BYA” in the gelprovided as FIG. 4. RP-HPLC (C₃) was used to separate the components ofthe resulting conjugate solution and the resulting chromatogram did notconfirm the presence of conjugated material. See the chromatagramprovided as FIG. 9.

It is expected that longer reactions times, increased temperaturesand/or multiple additions of the polymeric reagent could increaseyields. Using this same approach, other conjugates can be prepared usingbranched mPEG2-butyraldehyde having other weight-average molecularweights.

Example 13 PEGylation of Factor IX with Branched mPEG-Butyraldehyde, 20kDa (20:1 Polymer to Factor IX Ratio; without Ethanol)

Branched mPEG2-Butyraldehyde, 20 kDa, stored at −20° C. under argon, waswarmed to ambient temperature. The warmed branched mPEG2-butyraldehyde(10.9 mg) was dissolved in 1 mL of 2 mM HCl to form a branchedmPEG2-butyraldehyde solution. The branched mPEG2-butyraldehyde solutionwas added to an aliquot of the Factor IX stock solution containing 0.07mg of Factor IX until a twenty molar excess of branchedmPEG2-butyraldehyde to Factor LX was reached. After thirty minutes ofmixing, a reducing agent, NaCNBH₃ (dissolved in 1×PBS), was added atexcess relative to the branched mPEG2-butyraldehyde (with the pH testedand adjusted as necessary to ensure reduction to the secondary amine).The solution was then stirred overnight at 4° C. to ensure coupling viaan amine linkage.

RP-HPLC (C₃) and a SDS PAGE were used for the characterization of theresulting conjugate solution. Based on the SDS PAGE results, conjugationwas not detected. See the lane labeled as “20:1 20K BYA” in the gelprovided as FIG. 4. RP-HPLC (C₃) was used to separate the components ofthe resulting conjugate solution and the resulting chromatogram did notconfirm the presence of conjugated material. See the chromatogramprovided as FIG. 10.

It is expected that longer reactions times, increased temperaturesand/or multiple additions of the polymeric reagent could increaseyields. Using this same approach, other conjugates can be prepared usingbranched mPEG2-butyraldehyde having other weight-average molecularweights.

Example 14 PEGylation of Factor IX with mPEG-SPA, 20 kDa (53:1 Polymerto Factor IX Ratio; without Ethanol)

mPEG-SPA, 20 kDa, stored at −20° C. under argon, was warmed to ambienttemperature. The warmed mPEG-SPA (5.4 mg) was dissolved in 1 mL of 2 mMHCl to form an mPEG-SPA solution. The mPEG-SPA solution was added to analiquot of the Factor IX stock solution containing 0.07 mg of Factor IXuntil a fifty-three molar excess of mPEG-SPA relative to Factor IX wasreached. After the addition of the mPEG-SPA, the pH of the reactionmixture was tested to ensure a pH of 7.2 to 7.5. To allow for couplingof the mPEG-SPA to Factor IX via an amide linkage, the reaction solutionwas stirred for two hours at room temperature. Coupling was allowed tocontinue by stirring the reaction solution overnight at 4° C., therebyresulting in a conjugate solution.

RP-HPLC (C₃) and a second SDS PAGE were used for the characterization ofthe resulting conjugate solution. Based on the SDS PAGE results,conjugation was verified. See the lane labeled “53:1 20K SPA” in the gelprovided as FIG. 4. RP-HPLC (C₃) was used to separate the components ofthe resulting conjugate solution and the resulting chromatogramindicated approximately 60% conjugation yield (comprising 51.9%monoPEGylated or “1-mer” species and 8% diPEGylated or “2-mer” species).See the chromatogram provided as FIG. 11. It is believed, however, thatthe actual yield may be somewhat lower due to the relatively largeexcess of polymeric reagent.

Using this same approach, other conjugates can be prepared usingmPEG-SPA having other weight-average molecular weights.

Example 15 PEGylation of Factor IX with mPEG-SPA, 20 kDa (110:1 Polymerto Factor IX Ratio; without Ethanol)

mPEG-SPA, 20 kDa, stored at −20° C. under argon, was warmed to ambienttemperature. The warmed mPEG-SPA (5.4 mg) was dissolved in 1 mL of 2 mMHCl to form an mPEG-SPA solution. The mPEG-SPA solution was added to analiquot of the Factor IX stock solution containing 0.07 mg of Factor IXuntil a one hundred-ten molar excess of mPEG-SPA relative to Factor IXwas reached. After the addition of the mPEG-SPA, the pH of the reactionmixture was tested to ensure a pH of 7.2 to 7.5. To allow for couplingof the mPEG-SPA to Factor IX via an amide linkage, the reaction solutionwas stirred for two hours at room temperature. Coupling was allowed tocontinue by stirring the reaction solution overnight at 4° C., therebyresulting in a conjugate solution.

RP-HPLC (C₃) and a second SDS PAGE were used for the characterization ofthe resulting conjugate solution. Based on the SDS PAGE results,conjugation was verified. See the lane labeled “110:1 20K SPA” in thegel provided as FIG. 4. RP-HPLC (C₃) was used to separate the componentsof the resulting conjugate solution and the resulting chromatogramindicated approximately 44% conjugation yield (representingapproximately 100% monoPEGylated or “1-mer” species). See thechromatogram provided as FIG. 12. It is believed, however, that theactual yield may be somewhat lower due to the relatively large excess ofpolymeric reagent.

Using this same approach, other conjugates can be prepared usingmPEG-SPA having other weight-average molecular weights.

Example 16 PEGylation of Factor IX with Branched mPEG-Butyraldehyde, 20kDa (20:1 Polymer to Factor IX Ratio; with Ethanol)

As ethanol is believed to increase the structural flexibility of certainproteins, ethanol was introduced into the buffer and reaction system.Branched mPEG2-Butyraldehyde, 20 kDa, stored at −20° C. under argon, waswarmed to ambient temperature. The warmed branched mPEG2-butyraldehyde(10.9 mg) was dissolved in 1 mL of 2 mM HCl with ethanol added to form a10% ethanol-containing branched mPEG2-butyraldehyde solution. The 10%ethanol-containing branched mPEG2-butyraldehyde solution was added to analiquot of the Factor IX stock solution containing 0.07 mg of Factor IXuntil a twenty molar excess of branched mPEG2-butyraldehyde to Factor IXwas reached. After thirty minutes of mixing, a reducing agent, NaCNBH₃(dissolved in 1×PBS), was added at excess relative to the branchedmPEG2-butyraldehyde (with the pH tested and adjusted as necessary toensure reduction to the secondary amine). The solution was then stirredovernight at 4° C. to ensure coupling via an amine linkage.

RP-HPLC (C₃) and a SDS PAGE were used for the characterization of theresulting conjugate solution. Based on the SDS PAGE results, conjugationwas not detected. See the lane labeled as “20:1 20K BYA+EtOH” in the gelprovided as FIG. 4. RP-HPLC (C₃) confirmed the absence of detectableconjugated material (results not shown). It is now believed that theintroduction of ethanol does not increase the structural flexibility ofFactor IX to allow for increased conjugation of branchedmPEG2-butyraldehyde.

It is expected that longer reactions times, increased temperaturesand/or multiple additions of the polymeric reagent could increaseyields. Using this same approach, other conjugates can be prepared usingbranched mPEG2-butyraldehyde having other weight-average molecularweights.

Example 17 PEGylation of Factor IXa with mPEG-SBA

mPEG-Succinimidyl butanoate having a molecular weight of 10,000 Daltonsis obtained from Nektar Therapeutics, (Huntsville, Ala.). The basicstructure of the polymer reagent is provided below:

If lyophilized, Factor IXa is dissolved in amine-free buffer such asphosphate to result in a final pH to 7.2-9. To this solution is thenadded a 1.5 to 10-fold molar excess of mPEG-SBA. The resulting mixtureis stirred at room temperature for several hours.

The reaction mixture is analyzed by SDS-PAGE to determine the degree ofPEGylation of the protein.

Example 18 PEGylation of Factor IX with mPEG-PIP, 5K

The above polymeric reagent, shown as both the ketone and correspondingketal, is prepared as described in U.S. Patent Application PublicationNo. 2005/0031576.

To prepare the above polymeric reagent, to a solution ofmethoxy-polyethylene glycol-succinimidyl propionate having aweight-average molecular weight of 5,000 Daltons (1.0 g, 0.002 moles) inmethylene chloride (20 ml), triethyl amine (0.084 ml, 0.006 moles) and4-piperidone monohydrate hydrochloride (0.077 g, 0.005 moles) are added.The reaction mixture is stirred at room temperature under a nitrogenatmosphere overnight and then purified prior to conjugation.Alternatively, the polymer reagent may be purchased from NektarTherapeutics.

To effect conjugation, to a solution of Factor IX in aqueous buffer isadded a 20-fold molar excess of mPEG-PIP, 5K. The resulting solution isplaced on a Roto Mix™ orbital shaker (Thermolyne Corp., Dubuque, Iowa)set at slow speed to facilitate reaction at room temperature. After 15minutes, aqueous NaCNBH₃ is added in an amount equal to a 50 fold-molarexcess relative to Factor IX. Aliquots are withdrawn at timed intervalsfrom the reaction mixture and are analyzed by SDS-PAGE (using gelsavailable from Bio-Rad Laboratories, Hercules, Calif.).

SDS-PAGE analysis indicates the presence of PEG derivatives of Factor IXhaving 1, 2, and 3 PEG moieties attached.

Example 19 Conjugation of Cysteine-Inserted Factor IX with mPEG-MAL, 20K

Factor IX is inserted with one or more cysteine residues according tothe process described in WO 90/12874.

Prior to the conjugation, a buffer exchange for Factor IX is performedto replace histidine with HEPES.

mPEG-MAL, 20K, stored at −20° C. under argon, is warmed to ambienttemperature. The warmed mPEG-MAL reagent (4.4 mg) is dissolved in 0.044ml of HEPES buffer [50 mM HEPES (or other suitable buffer) pH 7.0] tomake a 10% mPEG-MAL solution. The mPEG-MAL solution is quickly added to4 ml of Factor IX solution [0.4324 mg/ml in 50 mM HEPES (or othersuitable formulation) pH 7.0] and is mixed well. After 30 minutes ofreaction at room temperature, the reaction vial is transferred to thecold room (4° C.), and another 0.044 ml of mPEG-MAL solution is added tothe reaction mixture, followed by the addition of three more aliquots of0.044 ml of mPEG-MAL solution over the course of two hours. The pH isdetermined (pH 7.0±0.2). The molar ratio of mPEG-MAL to protein is 50:1.The final mPEG-MAL concentration is 5.213 mg/ml, and the final Factor IXconcentration is 0.410 mg/ml. The reaction is allowed to proceedovernight at 4° C. on Rotomix (slow speed, Thermolyne).

The conjugate mixture is purified using gel filtration chromatography. Asize exclusion chromatography method is developed for analyzing thereaction mixtures, and the final products. SDS-PAGE analysis is alsoused for the characterization of the samples.

Example 20 In-vitro Activity of Exemplary Factor IX-PEG Conjugates

The biological activity of each of the Factor IX-PEG conjugatesdescribed in the Examples 1, 2, 3, 9, 14 and 15 are determined. All ofthe Factor IX-PEG conjugates tested are determined to have some degreeof Factor IX activity.

1. A unit dose of a pharmaceutical composition comprising (i) aconjugate comprising a Factor IX moiety covalently attached, eitherdirectly or through a spacer moiety comprised of one or more atoms, toat least one but not more than three water-soluble polymers, and (ii) apharmaceutically acceptable excipient, wherein the Factor IX moiety ispresent in an amount ranging from 0.001 mg to 100 mg.
 2. The unit doseof claim 1, wherein the Factor IX moiety is present in an amount rangingfrom 0.01 mg to 75 mg.
 3. The unit dose of claim 2, wherein the FactorIX moiety is present in an amount ranging from 0.10 mg to 50 mg.
 4. Theunit dose of claim 1, wherein the pharmaceutical composition is housedin a vial.
 5. The unit dose of claim 1, wherein the pharmaceuticalcomposition is housed in a syringe.
 6. The unit dose of claim 1, in aform suited for injection.
 7. The unit dose of claim 6, wherein thecomposition is in a powder form for reconstitution with a diluent priorto injection.
 8. The unit dose of claim 7, reconstituted with a diluent.9. The unit dose of claim 8, wherein the diluent is selected from thegroup consisting of bacteriostatic water for injection, five percentdextrose in water, phosphate buffered saline, Ringer's solution, saline,and sterile water.
 10. The unit dose of claim 1, wherein the excipientis present in an amount of about 15% to about 95% by weight.
 11. Theunit dose of claim 10, wherein the excipient is selected from the groupconsisting carbohydrates, inorganic salts, antimicrobial agents,antioxidants, surfactants, buffers, acids, bases, and combinationsthereof.
 12. The unit dose of claim 1, wherein the composition comprisesa plurality of conjugates, each having one, two, or three water-solublepolymers covalently attached to the Factor IX moiety.
 13. The unit doseof claim 1, wherein the composition comprises a conjugate having one ortwo water-soluble polymers covalently attached to the Factor IX moiety.14. The unit dose of claim 1, wherein the composition comprises aconjugate having one water-soluble polymer covalently attached to theFactor IX moiety (1-mer).
 15. The unit dose of claim 1, wherein thecomposition comprises a conjugate having two water-soluble polymerscovalently attached to the Factor IX moiety (2-mer).
 16. The unit doseof claim 1, wherein the composition comprises a conjugate having threewater-soluble polymers covalently attached to the Factor IX moiety(3-mer).
 17. The unit dose of claim 1, further comprising anunconjugated Factor IX moiety.
 18. The unit dose of claim 1, where whenthe Factor IX moiety is covalently attached to the at least one but notmore than three water-soluble polymers through a spacer moiety, thespacer moiety does not include a sugar or a carbohydrate.
 19. The unitdose of claim 1, wherein the at least one but not more than threewater-soluble polymers each have a total weight average molecular weightin a range of from about greater than 5,000 Daltons to less than about150,000 Daltons.
 20. The unit dose of claim 1, wherein the at least onebut not more than three water-soluble polymers in the composition areeach selected from the group consisting of a poly(alkylene glycol), apoly(oxyethylated polyol), a poly(olefinic alcohol), apoly(vinylpyrrolidone), a poly(hydroxyalkylmethacrylamide), apoly(hydroxyalkylmethacrylate), a poly(saccharide), a poly(α-hydroxyacid), a poly(vinyl alcohol), a polyphosphazene, a polyoxazoline, apoly(N-acryloylmorpholine), and combinations of any of the foregoing.21. The unit dose of claim 20, wherein each conjugate in the compositioncomprises the same water-soluble polymer.
 22. The unit dose of claim 21,wherein the at least one but not more than three water-soluble polymersare each either a poly(alkylene glycol) or a polysaccharide selectedfrom dextran and starch.
 23. The unit dose of claim 22, wherein thepoly(alkylene glycol) is a poly(ethylene glycol).
 24. The unit dose ofclaim 23, wherein the poly(ethylene glycol) is terminally capped with anend-capping moiety selected from the group consisting hydroxy, alkoxy,substituted alkoxy, alkenoxy, substituted alkenoxy, alkynoxy,substituted alkynoxy, aryloxy and substituted aryloxy.
 25. The unit doseof claim 24, wherein the poly(ethylene glycol) is terminally capped withmethoxy or hydroxy.
 26. The unit dose of claim 23, wherein thepoly(ethylene glycol) has a total weight average molecular weight in therange of from about 6,000 Daltons to about 100,000 Daltons.
 27. The unitdose of claim 23, wherein the poly(ethylene glycol) has a total weightaverage molecular weight in the range of from about 10,000 Daltons toabout 85,000 Daltons.
 28. The unit dose of claim 23, wherein thepoly(ethylene glycol) has a total weight average molecular weight in therange of from about 20,000 Daltons to about 85,000 Daltons.
 29. The unitdose of claim 23, wherein each poly(ethylene glycol) is linear.
 30. Theunit dose of claim 23, wherein each poly(ethylene glycol) is branched.31. The unit dose of claim 23, wherein the Factor IX moiety is FactorIX.
 32. The unit dose of claim 23, wherein the Factor IX moiety isFactor IXa.
 33. The unit dose of claim 23, wherein the Factor IX moietyis recombinantly-derived.
 34. The unit dose of claim 23, wherein theFactor IX moiety is blood-derived.
 35. The unit dose of claim 23, wherethe poly(ethylene glycol) is covalently attached to the Factor IX moietyvia a linkage selected from amide, amine, carbamate, thioether, anddisulfide.